DE69233745D1 - Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken - Google Patents

Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken

Info

Publication number
DE69233745D1
DE69233745D1 DE69233745T DE69233745T DE69233745D1 DE 69233745 D1 DE69233745 D1 DE 69233745D1 DE 69233745 T DE69233745 T DE 69233745T DE 69233745 T DE69233745 T DE 69233745T DE 69233745 D1 DE69233745 D1 DE 69233745D1
Authority
DE
Germany
Prior art keywords
mammal
rgdp
species
self
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233745T
Other languages
English (en)
Inventor
Andrew David Griffiths
Hendricus Renerus J Hoogenboom
James David Marks
John Mccafferty
Gregory Paul Winter
Geoffrey Walter Grigg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
MedImmune Ltd
Original Assignee
Medical Research Council
Cambridge Antibody Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450782&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69233745(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919125582A external-priority patent/GB9125582D0/en
Priority claimed from GB919125579A external-priority patent/GB9125579D0/en
Priority claimed from GB929206372A external-priority patent/GB9206372D0/en
Priority claimed from GB929206318A external-priority patent/GB9206318D0/en
Priority claimed from PCT/GB1992/001755 external-priority patent/WO1993006213A1/en
Application filed by Medical Research Council, Cambridge Antibody Technology Ltd filed Critical Medical Research Council
Application granted granted Critical
Publication of DE69233745D1 publication Critical patent/DE69233745D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
DE69233745T 1991-12-02 1992-12-02 Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken Expired - Lifetime DE69233745D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB919125582A GB9125582D0 (en) 1991-12-02 1991-12-02 Binding molecules 2
GB919125579A GB9125579D0 (en) 1991-07-10 1991-12-02 Binding molecules 1
GB929206372A GB9206372D0 (en) 1992-03-24 1992-03-24 Binding substances
GB929206318A GB9206318D0 (en) 1992-03-24 1992-03-24 Binding substances
PCT/GB1992/001755 WO1993006213A1 (en) 1991-09-23 1992-09-23 Production of chimeric antibodies - a combinatorial approach

Publications (1)

Publication Number Publication Date
DE69233745D1 true DE69233745D1 (de) 2008-10-23

Family

ID=27450782

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69233782T Expired - Lifetime DE69233782D1 (de) 1991-12-02 1992-12-02 Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
DE69233745T Expired - Lifetime DE69233745D1 (de) 1991-12-02 1992-12-02 Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69233782T Expired - Lifetime DE69233782D1 (de) 1991-12-02 1992-12-02 Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken

Country Status (7)

Country Link
US (10) US5885793A (de)
AT (3) ATE275198T1 (de)
DE (2) DE69233782D1 (de)
DK (1) DK1024191T3 (de)
ES (3) ES2341666T3 (de)
PT (2) PT1696031E (de)
WO (1) WO1993011236A1 (de)

Families Citing this family (1634)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005144A1 (en) * 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
PT1696031E (pt) * 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993019172A1 (en) * 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9225453D0 (en) * 1992-12-04 1993-01-27 Medical Res Council Binding proteins
DK0672142T3 (da) * 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
WO1995015388A1 (en) * 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
DK1231268T3 (da) 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
PT859841E (pt) * 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
WO1997022972A2 (en) * 1995-12-15 1997-06-26 Pharmacia & Upjohn Company Method for the simultaneous detection of a therapeutic target for a disease state and its neutralizing antibody-like molecule
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
US7227002B1 (en) * 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999015897A1 (en) * 1997-09-19 1999-04-01 Chiron Corporation Subtractive protein screening for gene identification
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
DE69938623T2 (de) 1998-02-04 2009-05-28 Invitrogen Corp., Carlsbad Microarrays und ihre verwendungen
US6479256B1 (en) 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
EP1982990A1 (de) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Zytokinrezeptor wie eine gemeinsame Gammakette
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
US7244826B1 (en) * 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
AU746040B2 (en) * 1998-04-24 2002-04-11 Regents Of The University Of California, The Targeted gene delivery to cells by filamentous bacteriophage
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
WO1999058655A2 (en) 1998-05-13 1999-11-18 Diversys Limited Phage display selection system for folded proteins
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
JP2002517223A (ja) 1998-06-12 2002-06-18 ジェネンテック・インコーポレーテッド モノクローナル抗体、交叉反応性抗体およびそれを生成する方法
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6780582B1 (en) * 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US20020119579A1 (en) * 1998-07-14 2002-08-29 Peter Wagner Arrays devices and methods of use thereof
US6576478B1 (en) * 1998-07-14 2003-06-10 Zyomyx, Inc. Microdevices for high-throughput screening of biomolecules
US20030138973A1 (en) * 1998-07-14 2003-07-24 Peter Wagner Microdevices for screening biomolecules
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
TR200102021T2 (tr) 1999-01-15 2001-12-21 Biogen, Inc. TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
WO2000044407A2 (en) 1999-02-01 2000-08-03 Amgen Canada Materials and methods to inhibit hodgkin and reed sternberg cell growth
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
JP2002537769A (ja) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ヒトエンドカインαおよび使用方法
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6890726B1 (en) 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
RU2294761C2 (ru) * 1999-05-14 2007-03-10 Имклон Систимс Инкопэритид Лечение резистентных опухолей человека антагонистами рецепторов фактора роста эпидермиса
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
JP4671570B2 (ja) 1999-08-23 2011-04-20 中外製薬株式会社 Ｈｍ１．２４抗原の発現増強剤
US7084256B2 (en) * 1999-09-24 2006-08-01 Large Scale Biology Corporation Self antigen vaccines for treating B cell lymphomas and other cancers
US20030044420A1 (en) * 1999-09-24 2003-03-06 Mccormick Alison A. Self antigen vaccines for treating B cell lymphomas and other cancers
US7037706B1 (en) 1999-09-29 2006-05-02 Xenoport, Inc. Compounds displayed on replicable genetic packages and methods of using same
AU7839700A (en) 1999-09-29 2001-04-30 Ronald W. Barrett Compounds displayed on replicable genetic packages and methods of using same
US6344549B1 (en) 1999-10-14 2002-02-05 Icos Corporation ATR-2 cell cycle checkpoint
CA2388599A1 (en) 1999-10-22 2001-05-03 Pharmacia & Upjohn Company Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US6498026B2 (en) 2000-02-25 2002-12-24 Hercules Incorporated Variant galactose oxidase, nucleic acid encoding same, and methods of using same
JP2003530847A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
EP1276855B1 (de) * 2000-04-17 2012-10-24 Dyax Corp. Verfahren zur einrichtung von bibliotheken für genetische verpackungen unterschiedlicher familien von peptiden
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
JP2004511753A (ja) * 2000-05-04 2004-04-15 イエール　ユニバーシティー タンパク質活性のスクリーニング用タンパク質チップ
EP1297112A2 (de) 2000-05-22 2003-04-02 PHARMACIA & UPJOHN COMPANY Neue matrix-metalloproteasen
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
CA2413160A1 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
EP2386575A3 (de) 2000-06-29 2011-11-30 Abbott Laboratories Antikörper mit Doppelspezifität und Verfahren zu deren Herstellung und Benutzung
US7067626B2 (en) 2000-07-05 2006-06-27 Pharmacia & Upjohn Company Human ion channel proteins
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
CA2418083A1 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
GB0022978D0 (en) 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
GB0025144D0 (en) * 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030026806A1 (en) * 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
CN1306272C (zh) * 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
EP2338512A1 (de) 2000-11-28 2011-06-29 MedImmune, LLC Verfahren zur Verabreichung/Dosierung von Anti-RSV-Antikörpern zur Prophylaxe und Behandlung
EP3569610A3 (de) 2000-12-12 2020-03-18 Medlmmune, LLC Moleküle mit verlängerter halbwertzeit, zusammensetzungen und verwendungen dafür
DE60144063D1 (de) 2000-12-18 2011-03-31 Dyax Corp Gerichtete bibliotheken die genetisch verpackt sind
ES2390425T3 (es) 2000-12-22 2012-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Uso de moléculas de orientación repulsivas (RGM) y sus moduladores
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2002086096A2 (en) * 2001-01-23 2002-10-31 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
AU2002251913A1 (en) * 2001-02-02 2002-08-19 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
WO2002064159A1 (en) 2001-02-07 2002-08-22 Chugai Seiyaku Kabushiki Kaisha Remedies for tumor in hematopoietic organs
JP2005503116A (ja) 2001-02-09 2005-02-03 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
CA2342376C (en) * 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) * 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) * 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
AU2002258602A1 (en) 2001-03-21 2002-10-08 Xenoport, Inc. Compounds displayed on icosahedral phage and methods of using same
IL158184A0 (en) * 2001-03-30 2004-03-28 Univ California Anti-muc-1 single chain antibodies for tumor targeting
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP1385864B1 (de) 2001-04-13 2010-06-09 Human Genome Sciences, Inc. Anti-VEGF-2 Antikörper
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
DK2163256T3 (en) 2001-05-11 2015-12-07 Ludwig Inst For Cancer Res Ltd Specific binding proteins and use thereof
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
CN101671335A (zh) * 2001-05-31 2010-03-17 梅达莱克斯公司 细胞毒素、其有用的前体药物、连接基团和稳定剂
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003035842A2 (en) * 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
US7175983B2 (en) * 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
DK1461428T3 (da) 2001-12-03 2012-06-04 Alexion Pharma Inc Fremgangsmåde til at fremstille hybridantistoffer
JP5424521B2 (ja) 2001-12-21 2014-02-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
AU2003214842A1 (en) * 2002-01-17 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
JP2005523688A (ja) * 2002-01-18 2005-08-11 ブリストル−マイヤーズ　スクイブ　カンパニー タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
WO2003104428A2 (en) * 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
ATE512163T1 (de) 2002-02-25 2011-06-15 Elan Pharm Inc Verabreichung von mitteln zur behandlung von entzündungen
EP2298346A3 (de) 2002-03-04 2011-11-16 Imclone LLC KDR-spezifische menschliche Antikörper und ihre Verwendung
US20030216551A1 (en) * 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
US20030186221A1 (en) * 2002-04-02 2003-10-02 Lockhart David J. Phage display affinity filter and forward screen
US7112435B1 (en) 2002-08-07 2006-09-26 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
EP2301577A3 (de) 2002-04-09 2012-08-08 Biogen Idec MA Inc. Verfahren zur Behandlung TWEAK-assoziierter Erkrankungen
US7371383B2 (en) 2002-04-12 2008-05-13 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
SI1517921T1 (sl) * 2002-06-28 2006-10-31 Domantis Ltd Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1539236A4 (de) * 2002-07-03 2007-07-18 Univ Pennsylvania Zusammensetzungen, verfahren und kits in verbindung mit anti-blutplättchen-autoantikörpern und inhibitoren davon
KR101257584B1 (ko) 2002-07-15 2013-04-23 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
AU2003257109A1 (en) * 2002-08-05 2004-02-23 Invitrogen Corporation Compositions and methods for molecular biology
US7833741B2 (en) * 2002-08-07 2010-11-16 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
US7897381B2 (en) * 2002-08-07 2011-03-01 Ambit Biosciences Corporation Uncoupling of DNA insert propagation and expression of protein for phage display
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
US20050233473A1 (en) * 2002-08-16 2005-10-20 Zyomyx, Inc. Methods and reagents for surface functionalization
US20060058511A1 (en) 2002-08-27 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing protein solution preparation
JP5525118B2 (ja) 2002-09-11 2014-06-18 中外製薬株式会社 タンパク質精製方法
WO2004035537A2 (en) 2002-10-16 2004-04-29 Euro-Celtique S.A. Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
GB2424070B (en) * 2002-11-14 2007-06-27 Univ Nottingham Methods for preparing tumour marker proteins
DE60333228D1 (de) * 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US6974860B2 (en) * 2002-12-30 2005-12-13 Kimberly-Clark Worldwide, Inc. Target recognizing binding agents
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2004065551A2 (en) * 2003-01-21 2004-08-05 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof
EP3527228A1 (de) 2003-01-24 2019-08-21 Biogen MA Inc. Zusammensetzung zur behandlung von demyelinisierungskrankheiten und lähmungen durch verabreichung von remyelinisierungsmitteln
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20040248798A1 (en) 2003-02-14 2004-12-09 Peter Sutovsky Contraceptive methods and compositions related to proteasomal interference
ES2347959T3 (es) 2003-02-20 2010-11-26 Seattle Genetics, Inc. Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer.
NZ607886A (en) 2003-03-19 2014-09-26 Biogen Idec Inc Nogo receptor binding protein
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US7638605B2 (en) 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
EP1627062A1 (de) 2003-05-14 2006-02-22 Domantis Limited Verfahren zur gewinnung aus einem polypeptid - repertoire von polypeptiden, die sich reversibel entfalten
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2004103272A2 (en) 2003-05-20 2004-12-02 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US8784821B1 (en) 2003-05-31 2014-07-22 Amgen Research (Munich) Gmbh Human-anti-human cd3 binding molecules
US20040248323A1 (en) * 2003-06-09 2004-12-09 Protometrix, Inc. Methods for conducting assays for enzyme activity on protein microarrays
JPWO2005017155A1 (ja) 2003-06-18 2006-10-12 中外製薬株式会社 フコーストランスポーター
JP4991291B2 (ja) 2003-06-20 2012-08-01 ディスカバーエクス コーポレイション タンパク質結合を検出するための検定法およびキット
JP2008500005A (ja) 2003-07-15 2008-01-10 バロス リサーチ インスティテュート 癌及び感染症の免疫療法のための組成物及び方法
JP5105874B2 (ja) 2003-07-18 2012-12-26 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合因子
US7619059B2 (en) * 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) * 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) * 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
EP2311468B1 (de) 2003-08-08 2014-01-15 Perseus Proteomics Inc. In Krebs überexprimiertes Gen
JP2007511738A (ja) 2003-08-08 2007-05-10 ジーンニュース インコーポレーテッド 変形性関節症のバイオマーカー及びその使用
EP2272566A3 (de) 2003-08-18 2013-01-02 MedImmune, LLC Humanisierung von antikörpern
DK1664343T3 (da) * 2003-09-09 2014-08-11 Integrigen Inc Fremgangsmåder og sammensætninger til generering af kimcelle humane antistofgener
US7046714B2 (en) * 2003-09-10 2006-05-16 Intel Corporation Method and apparatus for Raman ring resonator based laser/wavelength converter
CN1878793A (zh) * 2003-09-11 2006-12-13 鉴定医疗有限公司 拮抗hmgb1的单克隆抗体
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
WO2005035548A1 (en) 2003-10-10 2005-04-21 Meditech Research Limited The moduilation of hyaluronan synthesis and degradation in the treatment of disease
SI1983000T1 (sl) 2003-11-21 2015-12-31 Ucb Biopharma Sprl Postopek za zdravljenje multiple skleroze z zaviranjem aktivnosti il-17
CN1913921B (zh) * 2003-12-04 2012-02-22 瓦西尼斯公司 通过靶定暴露在细胞凋亡肿瘤细胞上的内部抗原杀死肿瘤细胞的方法
WO2005058815A2 (en) 2003-12-10 2005-06-30 Medarex, Inc. Ip-10 antibodies and their uses
LT2418220T (lt) 2003-12-10 2017-10-10 E. R. Squibb & Sons, L.L.C. Interferono-alfa antikūnai ir jų panaudojimas
FI3718564T3 (fi) 2003-12-23 2023-12-15 Genentech Inc Uusia anti-IL 13 -vasta-aineita ja niiden käyttöjä
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
AU2005207003C1 (en) 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
CA2555820C (en) 2004-02-19 2016-01-19 Genentech, Inc. Cdr-repaired antibodies
WO2005087177A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
DK1735348T3 (da) 2004-03-19 2012-07-16 Imclone Llc Humant anti-epidermalt vækstfaktorreceptorantistof
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005106038A2 (en) 2004-04-15 2005-11-10 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
EP1740617B1 (de) 2004-04-23 2013-10-16 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten Verfahren zur behandlung von erkrankungen, die mit t-zellen im zusammenhang stehen, durch eliminierung von icos-positiven zellen in vivo
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
NZ550934A (en) * 2004-05-19 2010-05-28 Medarex Inc Chemical linkers and conjugates thereof
EP1784427A2 (de) 2004-06-01 2007-05-16 Domantis Limited Bispezifische fusions-antikörper mit erhöhter serumhalbwärtszeit
SG188175A1 (en) * 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
CN101001878B (zh) 2004-06-21 2012-09-26 米德列斯公司 干扰素α受体1抗体及其用途
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
US8822644B2 (en) 2004-08-02 2014-09-02 Zenyth Operations Pty Ltd Method of treating cancer comprising a VEGF-B antagonist
JP5060293B2 (ja) 2004-08-03 2012-10-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経機能におけるｔａｊ
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP2008513540A (ja) 2004-09-21 2008-05-01 メディミューン，インコーポレーテッド 呼吸器合胞体ウイルスに対する抗体及び該ウイルス用のワクチンを製造する方法
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
AU2005299355A1 (en) 2004-10-27 2006-05-04 Medimmune, Llc Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006050257A2 (en) * 2004-10-29 2006-05-11 Massachusetts Institute Of Tecchnology Detection of ion channel or receptor activity
EP2377555A3 (de) 2004-11-18 2011-11-23 Imclone LLC Antikörper gegen den vaskulären endothelialen Wachstumsfaktorrezeptor-1
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
NZ555464A (en) 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
CN101072795B (zh) 2004-12-06 2014-07-02 协和发酵麒麟株式会社 针对流感病毒m2蛋白的人单克隆抗体
US20060134698A1 (en) * 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
US20080003617A1 (en) * 2004-12-20 2008-01-03 Xiaomin Fan Methods for the identification and the isolation of epitope specific antibodies
WO2006067134A1 (en) * 2004-12-22 2006-06-29 Laboratoires Serono S.A. Combination treatment for multiple sclerosis
EP1829961A4 (de) 2004-12-22 2008-06-04 Chugai Pharmaceutical Co Ltd Verfahren zur herstellung eines antikörpers unter verwendung einer zelle mit gehemmter fucosetransporterfunktion
CA2599589A1 (en) 2005-02-07 2006-08-17 Genenews,Inc. Mild osteoarthritis biomarkers and uses thereof
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
WO2006086733A2 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
HUE025945T2 (en) 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
US20060263357A1 (en) 2005-05-05 2006-11-23 Tedder Thomas F Anti-CD19 antibody therapy for autoimmune disease
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
CA2598522A1 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)
JP2008531730A (ja) 2005-03-04 2008-08-14 キュアーディーエム、インク． Ｉ型真性糖尿病及び他の症状を治療するための方法及び薬学的組成物
CA2602035C (en) 2005-03-18 2015-06-16 Medimmune, Inc. Framework-shuffling of antibodies
EP1870459B1 (de) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Verfahren zur polypeptidherstellung mit regulation des zusammenbaus
GB0506912D0 (en) 2005-04-05 2005-05-11 Celltech R&D Ltd Biological products
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
CA2605024C (en) 2005-04-15 2018-05-22 Macrogenics, Inc. Covalent diabodies and uses thereof
CN101203241B (zh) 2005-04-19 2012-02-22 西雅图基因公司 人源化抗-cd70结合物和其应用
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
EP2161336B2 (de) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Humane monoklonale Antikörper für den programmierten Tod 1 (PD-1) und Verfahren zur Behandlung von Krebs mit PD-1-Antikörpern allein oder in Kombination mit anderen Immunotherapeutika
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
EA013821B1 (ru) 2005-05-25 2010-08-30 Кьюрдм, Инк. Проостровковые пептиды человека, их производные и аналоги и способы их применения
SI1888113T1 (sl) 2005-05-27 2014-10-30 Biogen Idec Ma Inc. Protitelesa, ki veĹľejo TWEAK
GB2426581A (en) 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
NZ563466A (en) 2005-05-27 2009-12-24 Oncimmune Ltd Improved immunoassay methods
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
PT2314623E (pt) * 2005-06-21 2012-10-02 Xoma Technology Ltd Anticorpos de ligação a il-1β e os seus fragmentos
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
WO2007005955A2 (en) 2005-06-30 2007-01-11 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
NZ596992A (en) 2005-06-30 2013-07-26 Abbott Lab Il-12/p40 binding proteins
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
US7482124B2 (en) * 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
EP2238986A3 (de) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35-Antikörper und Verwendungen dafür
PL1912675T3 (pl) * 2005-07-25 2014-10-31 Emergent Product Dev Seattle Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
WO2007014433A1 (en) 2005-08-03 2007-02-08 Grains Research & Development Corporation Polysaccharide synthases
EP1919503B1 (de) 2005-08-10 2014-09-24 MacroGenics, Inc. Identifizierung und herstellung von antikörpern mit abweichenden fc-regionen und anwendungsverfahren dafür
JP2009504685A (ja) * 2005-08-15 2009-02-05 アラーナ・テラピューティクス・リミテッド 新世界霊長類フレームワーク領域を用いる設計された抗体
EP2500359A3 (de) 2005-08-19 2012-10-17 Abbott Laboratories Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
BRPI0615026A8 (pt) 2005-08-19 2018-03-06 Abbott Lab imunoglobulina de domínio variável duplo e seus usos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
CN101309703A (zh) * 2005-09-12 2008-11-19 诺维莫尼公司 抗cd3抗体组合物
CA2620362A1 (en) 2005-09-14 2007-03-22 Ucb Pharma S.A. Comb polymers
US20080279868A1 (en) 2005-09-26 2008-11-13 Medarex, Inc. Antibody-Drug Conjugates and Methods of Use
EA016186B1 (ru) 2005-09-26 2012-03-30 Медарекс, Инк. Человеческие моноклональные антитела к cd70 и их применение
EP1928905B1 (de) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
BRPI0617378B8 (pt) 2005-10-14 2022-09-20 Chugai Pharmaceutical Co Ltd Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
US8239136B2 (en) 2005-10-21 2012-08-07 Genenews Inc. Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
AU2006303452B2 (en) 2005-10-21 2011-06-09 Novartis Ag Human antibodies against IL13 and therapeutic uses
JP5191235B2 (ja) 2005-10-21 2013-05-08 中外製薬株式会社 心疾患治療剤
CN101365679B (zh) 2005-10-26 2012-11-14 梅达莱克斯公司 制备cc-1065类似物的方法和化合物
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
NZ568705A (en) 2005-11-04 2012-07-27 Biogen Idec Inc Methods for promoting neurite outgrowth and survival of dopaminergic neurons
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
EP2465870A1 (de) 2005-11-07 2012-06-20 Genentech, Inc. Bindepolypeptide mit verschiedenartigen und übereinstimmenden hypervariablen VH/VL-Sequenzen
US20100028358A1 (en) 2005-11-07 2010-02-04 Wolfram Ruf Compositions and Methods for Controlling Tissue Factor Signaling Specificity
WO2007059404A2 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
EP1964574B1 (de) 2005-11-14 2016-09-07 Cellmid Limited Verfahren zur behandlung oder prävention von krankheiten im zusammenhang mit funktionalen störungen der regulatorischen t-zelle
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
EP2567973B1 (de) 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21-Antagonisten
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
KR101906161B1 (ko) * 2005-11-30 2018-10-11 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
JP5312039B2 (ja) 2005-12-02 2013-10-09 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脱髄の関与する状態の処置
US8957187B2 (en) 2005-12-02 2015-02-17 Genentech, Inc. Binding polypeptides and uses thereof
PT1960434E (pt) 2005-12-08 2012-10-02 Medarex Inc Anticorpos monoclonais humanos para fucosil-gm1 e métodos para a utilização de anti-fucosil-gm1
DK1960430T3 (da) 2005-12-09 2015-01-05 Ucb Pharma Sa Antistofmolekyler der har specificitet for humant il-6
EP1803814A1 (de) * 2005-12-27 2007-07-04 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Methode zur Verbesserung der Antikörperselektionskapazität in einer Phagen-Display-Bibliothek
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
CN102887954B (zh) 2005-12-29 2015-02-04 詹森生物科技公司 人抗il-23抗体、组合物、方法和用途
US20070160325A1 (en) * 2006-01-11 2007-07-12 Hyungbin Son Angle-tunable transmissive grating
US20070166774A1 (en) * 2006-01-17 2007-07-19 Groman Ernest V Functional immunoassay
WO2007086490A1 (ja) 2006-01-27 2007-08-02 Keio University 脈絡膜血管新生を伴う疾患の治療剤
BRPI0707276B1 (pt) 2006-01-27 2021-08-31 Biogen Ma Inc Polipeptídeo de fusão antagonista de receptor nogo
US20080038761A1 (en) * 2006-01-30 2008-02-14 Invitrogen Corporation Compositions and methods for detecting and quantifying toxic substances in disease states
JP5259423B2 (ja) * 2006-02-01 2013-08-07 セファロン・オーストラリア・ピーティーワイ・リミテッド ドメイン抗体構築物
EP1999148B8 (de) 2006-03-06 2014-03-05 Medlmmune, LLC Humanisierte anti-cd22-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
EP3056568B1 (de) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Verfahren zur kontrolle der blutpharmakokinetik von antikörpern
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
CA2648644C (en) 2006-04-07 2016-01-05 Osaka University Muscle regeneration promoter
WO2007119796A1 (ja) 2006-04-14 2007-10-25 Medical And Biological Laboratories Co., Ltd. エフェクター機能を有するポリペプチド変異体
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
KR20150091545A (ko) 2006-06-08 2015-08-11 추가이 세이야쿠 가부시키가이샤 염증성 질환의 예방 또는 치료제
NZ596865A (en) * 2006-06-12 2013-07-26 Emergent Product Dev Seattle Single-chain multivalent binding proteins with effector function
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
JP5764290B2 (ja) 2006-06-26 2015-08-19 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体およびその使用法
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
JPWO2008007755A1 (ja) 2006-07-13 2009-12-10 中外製薬株式会社 細胞死誘導剤
ME00581B (me) 2006-07-18 2011-12-20 Sanofi Aventis Antagonisticna antitijela za tretman kancera polje pronalaska
JP5175729B2 (ja) 2006-07-21 2013-04-03 中外製薬株式会社 腎疾患治療剤
ES2396220T3 (es) 2006-08-11 2013-02-20 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1)
PL2056858T3 (pl) * 2006-08-11 2015-01-30 Csl Ltd Leczenie stanów chorobowych płuc
AU2007285217B2 (en) 2006-08-14 2013-02-07 Forerunner Pharma Research Co., Ltd Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
MX2009001829A (es) 2006-08-18 2009-05-28 Novartis Ag Anticuerpo especifico prlr y sus usos.
DK2292663T3 (da) 2006-08-28 2013-11-04 Kyowa Hakko Kirin Co Ltd Antagonistiske human-let-specifikke, humane monoklonale antistoffer
JP2010502220A (ja) 2006-09-05 2010-01-28 メダレックス インコーポレーティッド 骨形態形成タンパク質およびその受容体に対する抗体ならびにその使用方法
KR101676269B1 (ko) 2006-09-08 2016-11-15 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
CN101632020B (zh) 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
EP2083017A4 (de) 2006-09-14 2011-01-12 Med & Biological Lab Co Ltd Antikörper mit verbesserter adcc-wirkung und verfahren zu dessen herstellung
US20090252745A1 (en) * 2006-09-15 2009-10-08 Duke University Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis
US8784807B2 (en) 2006-09-22 2014-07-22 St. Jude Children's Research Hospital Method of inhibiting regulatory T-cell activity by administering an antibody that inhibits interleukin 35
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CN103897058B (zh) 2006-10-02 2018-06-15 E.R.施贵宝&圣斯有限责任公司 结合cxcr4的人类抗体及其用途
NZ601022A (en) 2006-10-12 2014-09-26 Chugai Pharmaceutical Co Ltd Diagnosis and treatment of cancer using anti-ereg antibody
JP2010506842A (ja) 2006-10-16 2010-03-04 メディミューン，エルエルシー 半減期が短縮された分子、その組成物および使用
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
DK2068922T3 (da) 2006-10-19 2012-10-08 Csl Ltd Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
EP2829551B1 (de) 2006-10-19 2017-12-13 CSL Limited Hochaffine Antikörperantagonisten des Interleukin-13-Rezeptors Alpha 1
EP1914242A1 (de) 2006-10-19 2008-04-23 Sanofi-Aventis Neue Antikörper gegen CD38 zur Behandlung von Krebs
CA2666809A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Anti-cancer agent comprising anti-hb-egf antibody as active ingredient
AU2007311957A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
CN101573381A (zh) 2006-11-09 2009-11-04 Irm责任有限公司 激动剂TrkB抗体及其用途
JP2010509920A (ja) 2006-11-15 2010-04-02 メダレックス インコーポレーティッド Ｂｔｌａに対するヒトモノクローナル抗体および使用方法
WO2008064306A2 (en) 2006-11-22 2008-05-29 Curedm, Inc. Methods and compositions relating to islet cell neogenesis
EP2431053A1 (de) 2006-11-27 2012-03-21 Patrys Limited Neues glykosyliertes Zielpeptid in neoplastischen Zellen
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US8067179B2 (en) 2006-11-30 2011-11-29 Research Development Foundation Immunoglobulin libraries
CA2699837C (en) 2006-12-01 2017-06-13 Seattle Genetics, Inc. Variant target binding agents and uses thereof
ES2678060T3 (es) 2006-12-01 2018-08-08 E. R. Squibb & Sons, L.L.C. Anticuerpos, en particular, anticuerpos humanos, que se unen a CD22 y usos de los mismos
EP2687232A1 (de) 2006-12-06 2014-01-22 MedImmune, LLC Verfahren zur Behandlung von systemischem Lupus erythematodes
AU2007329307B2 (en) 2006-12-07 2012-08-02 Novartis Ag Antagonist antibodies against EphB3
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
US20100111852A1 (en) 2006-12-14 2010-05-06 Forerunner Pharma Research Co., Ltd. Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
NZ577274A (en) 2006-12-18 2012-10-26 Genentech Inc Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
US7695718B2 (en) 2006-12-20 2010-04-13 Xoma Technology Ltd. Methods for the treatment of IL-1β related diseases
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
WO2008082651A2 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
EP2123676A4 (de) 2007-01-05 2011-01-05 Univ Tokyo Diagnose und behandlung von krebs unter verwendung von anti-prg-3-antikörpern
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
PT2740744T (pt) 2007-01-09 2018-06-06 Biogen Ma Inc Anticorpos sp35 e suas utilizações
KR20150038227A (ko) 2007-01-16 2015-04-08 애브비 인코포레이티드 건선의 치료방법
BRPI0806812B8 (pt) 2007-01-23 2021-09-14 Chugai Pharmaceutical Co Ltd Agente para suprimir reação de rejeição crônica e uso de um inibidor de il-6
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
SI2129396T1 (sl) 2007-02-16 2013-12-31 Merrimack Pharmaceuticals, Inc. Protitelesa proti ErbB3 in njihove uporabe
WO2008101184A2 (en) 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
WO2008103474A1 (en) * 2007-02-20 2008-08-28 Anaptysbio, Inc. Methods of generating libraries and uses thereof
CL2008000510A1 (es) 2007-02-21 2008-08-22 Medarex Inc Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP3118221B1 (de) 2007-02-26 2019-08-21 Oxford BioTherapeutics Ltd Proteine
CN101951953A (zh) 2007-02-27 2011-01-19 株式会社未来创药研究所 含抗grp78抗体作为有效成分的药物组合物
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
SI2125894T1 (sl) 2007-03-22 2019-05-31 Biogen Ma Inc. Vezavne beljakovine, vključno s protitelesi, derivati protiteles in fragmenti protiteles, ki specifično vežejo CD154, ter njihove uporabe
KR101540823B1 (ko) 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
CA2682851C (en) 2007-04-02 2017-01-17 Philogen S.P.A. A novel antigen associated with the neovasculature of tumour metastases
BRPI0810374A2 (pt) 2007-04-17 2014-10-29 Imclone Llc Inibidores específicos do pdgfrbeta
AU2008247819B2 (en) * 2007-05-01 2013-02-14 Research Development Foundation Immunoglobulin Fc libraries
PT2164868E (pt) 2007-05-04 2015-08-04 Technophage Investigaçao E Desenvolvimento Em Biotecnologia Sa Domínios variáveis de anticorpos de coelho manipulados e suas utilizações
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
PL2068927T3 (pl) 2007-05-14 2016-06-30 Medimmune Llc Sposoby redukcji poziomów eozynofilii
JP5117765B2 (ja) 2007-05-28 2013-01-16 国立大学法人 東京大学 抗ｒｏｂｏ１抗体を含むｐｅｔ用腫瘍診断剤
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
KR20100018040A (ko) 2007-06-06 2010-02-16 도만티스 리미티드 프로테아제 내성 폴리펩티드를 선택하는 방법
CN107226864A (zh) 2007-06-21 2017-10-03 宏观基因有限公司 共价双抗体及其用途
WO2009023386A2 (en) * 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
ES2614735T3 (es) 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
WO2009013319A1 (en) * 2007-07-23 2009-01-29 Bioxell Spa Screening, therapy and diagnosis
CN101754978B (zh) 2007-07-25 2013-06-05 菲洛根股份公司 一种与肺癌和淋巴瘤相关的抗原
EP3246045A1 (de) 2007-07-26 2017-11-22 Osaka University Therapeutische mittel für entzündliche augenerkrankung mit interleukin-6-rezeptor-inhibitor als wirkstoff
CA2695237A1 (en) 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
EP2615114B1 (de) 2007-08-23 2022-04-06 Amgen Inc. Antigenbindende Proteine an Proprotein-Konvertase-Subtilisin/Kexin vom Typ 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
SG10201407388XA (en) 2007-08-29 2015-01-29 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
NZ599756A (en) 2007-08-30 2013-09-27 Curedm Group Holdings Llc Compositions and methods of using proislet peptides and analogs thereof
SI2199390T1 (sl) 2007-08-30 2017-02-28 Daiichi Sankyo Company, Limited Proti-epha2 protitelo
US8415455B2 (en) 2007-09-04 2013-04-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
EP3124497B1 (de) 2007-09-14 2020-04-15 Adimab, LLC Synthetische antikörperbibliotheken mit rationalem design und verwendungen davon
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2535351A3 (de) 2007-09-26 2013-04-03 UCB Pharma S.A. Antikörperfusionen mit Doppelspezifität
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
DK2196541T3 (da) 2007-09-28 2012-11-26 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antistof med forbedret kinetik i plasmaet
WO2009044774A1 (ja) 2007-10-02 2009-04-09 Chugai Seiyaku Kabushiki Kaisha インターロイキン６受容体阻害剤を有効成分とする移植片対宿主病治療剤
SG187523A1 (en) 2007-10-11 2013-02-28 Daiichi Sankyo Co Ltd Antibody targeting osteoclast-related protein siglec-15
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
CN101802192A (zh) 2007-10-15 2010-08-11 中外制药株式会社 抗体的制备方法
EP2214706A1 (de) 2007-10-23 2010-08-11 Novartis AG Verwendung von trkb-antikörpern zur behandlung von atemwegserkrankungen
JP5620106B2 (ja) 2007-10-24 2014-11-05 株式会社糖鎖工学研究所 増強されたエフェクター機能を有するポリペプチド
CN103396483B (zh) 2007-10-30 2016-11-23 菲洛根股份公司 一种与类风湿性关节炎相关的抗原
EP3305324A1 (de) 2007-11-02 2018-04-11 Novartis AG Moleküle und verfahren zur modulation eines lipoproteinrezeptorassoziierten proteins 6 (lrp6) mit geringer dichte
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
CN101888856B (zh) 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
CN102112492B (zh) 2007-11-14 2015-02-25 中外制药株式会社 使用抗gpr49抗体的癌症的诊断和治疗
PE20091024A1 (es) 2007-11-15 2009-08-12 Chugai Pharmaceutical Co Ltd Anticuerpos monoclonales que se unen a anexelekto y sus usos
JP5616230B2 (ja) 2007-11-16 2014-10-29 ザ ロックフェラー ユニバーシティー ベータ−アミロイドタンパク質のプロトフィブリルの形態に特異的な抗体
US7892760B2 (en) 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
AR069393A1 (es) 2007-11-21 2010-01-20 Imclone Systems Inc Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
JP5781764B2 (ja) 2007-11-27 2015-09-24 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア １４−３−３η抗体、並びに関節炎の診断及び治療のためのその使用
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
WO2009068649A2 (en) 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs
MY185647A (en) 2007-12-05 2021-05-27 Chugai Pharmaceutical Co Ltd Therapeutic agent for pruritus
TW201634479A (zh) 2007-12-05 2016-10-01 Chugai Pharmaceutical Co Ltd 抗ｎｒ１０抗體及其應用
WO2009075344A1 (ja) 2007-12-12 2009-06-18 Japan As Represented By Director General Of Agency Of National Cancer Center M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
US7960515B2 (en) 2007-12-14 2011-06-14 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
CA3102679A1 (en) 2007-12-14 2009-06-25 Birgitte Urso Antibodies against human nkg2d and uses thereof
EP2851373A1 (de) * 2007-12-20 2015-03-25 Xoma (Us) Llc Verfahren zur Behandlung von Gicht
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CA2708871C (en) 2007-12-21 2017-11-21 Medimmune Limited Binding members for interleukin-4 receptor alpha (il-4r.alpha.) - 173
EP2235058A2 (de) 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid-antikörper und ihre verwendung
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
JP5690593B2 (ja) 2007-12-26 2015-03-25 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
GB0800277D0 (en) 2008-01-08 2008-02-13 Imagination Tech Ltd Video motion compensation
US8821863B2 (en) 2008-01-11 2014-09-02 Gene Techno Science Co., Ltd. Humanized anti-α 9 integrin antibodies and the uses thereof
US9274119B2 (en) 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
KR20100107501A (ko) 2008-01-18 2010-10-05 메디뮨 엘엘씨 부위 특이적 접합을 위한 시스테인 조작 항체
AU2009206306B2 (en) 2008-01-25 2013-06-06 Amgen Inc. Ferroportin antibodies and methods of use
WO2009099961A2 (en) 2008-01-31 2009-08-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Engineered antibody constant domain molecules
US8039596B2 (en) 2008-02-05 2011-10-18 Bristol-Myers Squibb Company Alpha 5-beta 1 antibodies and their uses
DK2250279T3 (en) 2008-02-08 2016-08-01 Medimmune Llc ANTI-IFNAR1 antibodies with reduced Fc ligand affinity-
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
MX2010010021A (es) 2008-03-12 2011-02-15 Imclone Llc Anticuepos anti-tyrp1.
US9873957B2 (en) 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
CN102937653B (zh) 2008-03-14 2015-09-09 阿勒根公司 基于免疫的血清型a肉毒杆菌毒素活性测定
AU2009225797A1 (en) 2008-03-18 2009-09-24 Abbvie Inc. Methods for treating psoriasis
US20110020368A1 (en) 2008-03-25 2011-01-27 Nancy Hynes Treating cancer by down-regulating frizzled-4 and/or frizzled-1
BRPI0906261A2 (pt) 2008-03-31 2015-07-07 Genentech Inc "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
PT2247304T (pt) 2008-04-02 2016-08-29 Macrogenics Inc Anticorpos especificos de her2/neu e métodos de utilização dos mesmos
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
CN102056626B (zh) 2008-04-11 2016-07-06 西雅图遗传学公司 胰腺癌、卵巢癌和其它癌症的检测和治疗
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN102099377A (zh) * 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
KR101746861B1 (ko) 2008-04-24 2017-06-14 가부시키가이샤 진 테크노 사이언스 세포 외 기질 단백질의 아미노산 서열 ｒｇｄ에 특이적인 인간화된 항체 및 그의 용도
WO2009132287A2 (en) 2008-04-24 2009-10-29 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PT2281006T (pt) 2008-04-30 2017-12-06 Immunogen Inc Agentes de reticulação e as suas utilizações
ES2487846T3 (es) 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
ES2458541T3 (es) 2008-05-02 2014-05-06 Seattle Genetics, Inc. Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
MX343624B (es) 2008-05-09 2016-11-14 Abbott Laboratories * Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
US9226934B2 (en) 2008-06-02 2016-01-05 The University Of Tokyo Anti-cancer drug
WO2009149185A2 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
ES2675730T3 (es) 2008-06-04 2018-07-12 Macrogenics, Inc. Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
DK2293816T3 (da) * 2008-06-06 2013-02-04 Xoma Technology Ltd Fremgangsmåder til behandling af reumatoid arthritis
NZ589795A (en) 2008-06-16 2013-02-22 Patrys Ltd Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
CN102124030B (zh) 2008-06-20 2015-06-17 国立大学法人冈山大学 抗氧化LDL/β2GPI复合物的抗体及其用途
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
EP2810654A1 (de) 2008-07-08 2014-12-10 AbbVie Inc. Prostaglandin-E2 bindende Proteine und ihre Verwendung
NZ590131A (en) 2008-07-08 2012-10-26 Oncomed Pharm Inc Notch-binding agents and antagonists and methods of use thereof
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
WO2010010469A2 (en) * 2008-07-25 2010-01-28 Abbott Gmbh & Co. Kg Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
WO2010011944A2 (en) 2008-07-25 2010-01-28 Wagner Richard W Protein screeing methods
HUE026179T2 (en) 2008-08-05 2016-05-30 Novartis Ag Preparations and methods for antibodies against complement C5 protein
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
CA2735940A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for treating or preventing il-1.beta. related diseases
WO2010027364A1 (en) 2008-09-07 2010-03-11 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
CA2741523C (en) 2008-10-24 2022-06-21 Jonathan S. Towner Human ebola virus species and compositions and methods thereof
DK2356269T3 (en) 2008-10-31 2016-08-15 Janssen Biotech Inc FIBRONECTIN TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, PROCEDURES AND APPLICATIONS
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
WO2010052288A1 (en) 2008-11-07 2010-05-14 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
JP5840498B2 (ja) 2008-12-05 2016-01-06 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ プロテアーゼ耐性ポリペプチドを選択するための方法
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
CN102245771B (zh) 2008-12-16 2013-04-10 诺瓦提斯公司 酵母展示***
KR101940059B1 (ko) 2008-12-19 2019-01-18 마크로제닉스, 인크. 공유결합형 디아바디 및 이의 용도
US20120014870A1 (en) 2008-12-26 2012-01-19 Forerunner Pharma Research Co., Ltd. Diagnosis and Treatment of Cancer Using Anti-LGR7 Antibody
US20120003235A1 (en) 2008-12-31 2012-01-05 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
EP2379116B1 (de) 2009-01-07 2015-08-26 Philogen S.p.A. Mit endometriose assoziierte antigene
GB0900425D0 (en) 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
WO2010082134A1 (en) 2009-01-14 2010-07-22 Iq Therapeutics Bv Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
WO2010085510A1 (en) 2009-01-20 2010-07-29 Zadeh Homayoun H Antibody mediated osseous regeneration
US20120058131A1 (en) 2009-01-21 2012-03-08 Oxford Biotherapeutics Ltd Pta089 protein
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
JP5977522B2 (ja) 2009-02-05 2016-08-24 イミュノジェン・インコーポレーテッド 新規ベンゾジアゼピン誘導体
WO2010093450A2 (en) 2009-02-11 2010-08-19 Ludwing Institute For Cancer Research Ltd. Pten phosphorylation-driven resistance to cancer treatment and altered patient prognosis
EP2396011B1 (de) 2009-02-12 2016-04-13 Janssen Biotech, Inc. Auf fibronectin-typ-iii-domain basierende gerüstzusammensetzungen, verfahren und anwendung
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
US8614295B2 (en) 2009-02-17 2013-12-24 Ucb Pharma S.A. Antibody molecules having specificity for human OX40
WO2010097394A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
WO2010097385A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US20110305693A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Anitigen-binding constructs
BRPI1009232B1 (pt) 2009-03-05 2022-05-03 E.R. Squibb & Sons, Llc. Anticorpo monoclonal isolado ou uma porção de ligação de antígeno do mesmo, ou um fragmento de anticorpo, composição que os compreende, molécula de ácido nucleico, hibridoma e métodos para a preparação de um anticorpo anti-cadm1
WO2010102251A2 (en) 2009-03-05 2010-09-10 Abbott Laboratories Il-17 binding proteins
WO2010100247A1 (en) 2009-03-06 2010-09-10 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
WO2010104208A1 (en) 2009-03-10 2010-09-16 Gene Techno Science Co., Ltd. Generation, expression and characterization of the humanized k33n monoclonal antibody
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2570809A1 (de) 2009-03-13 2013-03-20 Allergan, Inc. Immunobasierte neu ausgerichtete Endopeptidaseaktivitätstests
WO2010111702A1 (en) 2009-03-27 2010-09-30 The Research Foundation Of State University Of New York Methods for preventing and treating angioedema
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
EP3061463A1 (de) 2009-04-08 2016-08-31 LipUm AB Neue verfahren zur behandlung von entzündungserkrankungen
MX2011007342A (es) 2009-04-09 2011-07-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
EP2417984B1 (de) 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Verfahren zur behandlung von blutkrebs mittels anti-tim-antikörper
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
WO2010121140A1 (en) 2009-04-16 2010-10-21 Facet Biotech Corporation ANTI-TNF-α ANTIBODIES AND THEIR USES
SG175734A1 (en) 2009-04-20 2011-12-29 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
WO2010124113A1 (en) 2009-04-23 2010-10-28 Infinity Pharmaceuticals, Inc. Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
NZ595235A (en) 2009-04-27 2013-06-28 Novartis Ag Compositions and methods for increasing muscle growth
JP5694923B2 (ja) 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
CA2759942A1 (en) 2009-04-27 2010-10-07 Novartis Ag Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betai subunit
CN102753579A (zh) 2009-05-01 2012-10-24 国立大学法人东京大学 抗钙粘着蛋白抗体
BRPI1014445A8 (pt) 2009-05-04 2018-01-09 Abbott Res Bv anticorpos contra fator de crescimento de nervo (ngf) com estabilidade in vivo intensificada
MX2011011729A (es) 2009-05-05 2012-04-10 Novimmune Sa Anticuerpo anti il-17f y metodos de uso de los mismos.
EP2270053A1 (de) 2009-05-11 2011-01-05 U3 Pharma GmbH Humanisierte AXL-Antikörper
AU2010249470B2 (en) * 2009-05-20 2015-06-25 Novimmune S.A. Synthetic Polypeptide Libraries And Methods For Generating Naturally Diversified Polypeptide Variants
EP2435475B1 (de) 2009-05-26 2018-10-17 Icahn School of Medicine at Mount Sinai Mittels zyklischer verabreichung erzeugte monoklonale antikörper gegen influenzavirus und ihre anwendung
EP2435568B1 (de) 2009-05-29 2014-07-02 MorphoSys AG Kollektion synthetischer Antikörper zur Behandlung von Krankheiten
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
KR102560218B1 (ko) 2009-06-03 2023-07-26 이뮤노젠 아이엔씨 접합 방법
BRPI1012321A8 (pt) 2009-06-17 2016-09-27 Abbott Biotherapeutics Corp Anticorpos anti-vegf e seus usos
EP2711018A1 (de) 2009-06-22 2014-03-26 MedImmune, LLC Manipulierte Fc-Regionen für standortspezifische Konjugation
EP2445925A1 (de) 2009-06-25 2012-05-02 Bristol-Myers Squibb Company Proteinaufreinigung mittels präzipitation von caprylsäure (octansäure)
JP5683581B2 (ja) * 2009-06-30 2015-03-11 リサーチ ディベロップメント ファウンデーション 免疫グロブリンＦｃポリペプチド
JP2012531212A (ja) 2009-07-03 2012-12-10 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
EP2459585A1 (de) 2009-07-30 2012-06-06 Mount Sinai School of Medicine Influenzaviren und ihre verwendung
SG178190A1 (en) 2009-07-31 2012-03-29 Shin Maeda Cancer metastasis inhibitor
CN102656189B (zh) 2009-08-13 2014-10-08 克鲁塞尔荷兰公司 针对人呼吸道合胞病毒(rsv)的抗体以及使用方法
CN102574917A (zh) 2009-08-17 2012-07-11 株式会社未来创药研究所 含有抗hb-egf抗体作为有效成分的药物组合物
WO2011021146A1 (en) 2009-08-20 2011-02-24 Pfizer Inc. Osteopontin antibodies
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
CN105131112A (zh) 2009-08-29 2015-12-09 Abbvie公司 治疗用dll4结合蛋白
CA2772628A1 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
US20120283415A1 (en) 2009-09-10 2012-11-08 Ucb Pharma S.A. Multivalent Antibodies
EP2478136A4 (de) * 2009-09-14 2013-09-25 Dyax Corp Bibliotheken aus genetischen packungen mit neuen hc-cdr3-entwürfen
RU2012114854A (ru) 2009-09-14 2013-10-27 Эбботт Лэборетриз Способы лечения псориаза
PL2477656T3 (pl) 2009-09-15 2017-09-29 Csl Limited Leczenie stanów neurologicznych
MX2012003396A (es) 2009-09-16 2012-04-10 Genentech Inc Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
WO2011036118A1 (en) 2009-09-22 2011-03-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
EP2480561B1 (de) 2009-09-23 2016-07-13 E. R. Squibb & Sons, L.L.C. Kationenaustauschchromatographie
WO2011038139A1 (en) 2009-09-23 2011-03-31 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
CA2776037A1 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd Anti-fibroblast activation protein antibodies and methods and uses thereof
WO2011040973A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
IN2012DN02780A (de) 2009-10-06 2015-09-18 Immunogen Inc
PT2486141T (pt) 2009-10-07 2018-05-09 Macrogenics Inc Polipéptidos contendo uma região fc que apresenta uma função efectora melhorada, devido a modificações do grau de fucosilação, e métodos para a sua utilização
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
EP2470569A1 (de) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antikörper gegen epha10
US8580714B2 (en) 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
PE20121531A1 (es) 2009-10-15 2012-12-22 Abbott Lab Inmunoglobulinas con dominio variable dual
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
ES2639056T3 (es) 2009-10-28 2017-10-25 Abbvie Biotherapeutics Inc. Anticuerpos anti-EGFR y sus usos
MX2012005086A (es) 2009-10-30 2012-09-28 Janssen Biotech Inc Antagonistas de il-17a.
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
AU2010315101B2 (en) 2009-11-04 2016-01-28 Fabrus Llc Methods for affinity maturation-based antibody optimization
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
EP2496604B1 (de) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Antikörper gegen hunde-cd20
WO2011058087A1 (en) 2009-11-11 2011-05-19 Gentian As Immunoassay for assessing related analytes of different origin
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
EP3431608A3 (de) 2009-11-17 2019-02-20 E. R. Squibb & Sons, L.L.C. Verfahren zur erhöhten proteinproduktion
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
US20130183326A9 (en) 2009-11-20 2013-07-18 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
CA2780069C (en) 2009-12-08 2018-07-17 Abbott Gmbh & Co. Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
JP2013513380A (ja) 2009-12-09 2013-04-22 アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル・（イ・エヌ・エス・ウ・エール・エム） Ｂ７ｈ６と結合するモノクローナル抗体およびその使用
EP2513148B1 (de) 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2-antikörper und ihre verwendung
EP2516462B1 (de) 2009-12-23 2015-05-06 Avipep Pty Ltd Immunkonjugate und verfahren zu ihrer herstellung
US9005579B2 (en) 2010-01-05 2015-04-14 Contrafect Corporation Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
MX2012008085A (es) 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
WO2011092989A1 (ja) 2010-01-29 2011-08-04 東レ株式会社 ポリ乳酸系樹脂シート
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
US20120296403A1 (en) 2010-02-10 2012-11-22 Novartis Ag Methods and compounds for muscle growth
KR101900110B1 (ko) 2010-02-10 2018-09-18 후지필름 알아이 파르마 가부시키가이샤 방사성 금속 표지 항카드헤린 항체
KR20120117931A (ko) 2010-02-12 2012-10-24 온코메드 파마슈티칼스, 인크. 폴리펩타이드를 발현하는 세포를 확인 및 분리하는 방법
US10393754B2 (en) 2010-02-17 2019-08-27 Cedars-Sinai Medical Center Methods of diagnosing and treating heart failure
BR112012020839A2 (pt) 2010-02-18 2017-11-21 Sinai School Medicine vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
CA3014767C (en) 2010-02-24 2023-08-29 Immunogen, Inc. Folate receptor 1 antibodies and immunoconjugates and uses thereof
MX348312B (es) 2010-03-02 2017-06-06 Abbvie Inc Proteínas terapéuticas de enlace dll4.
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
EP2542578A1 (de) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c und hirnkrebs
AU2011226672B2 (en) 2010-03-12 2015-07-23 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
AR080685A1 (es) 2010-03-17 2012-05-02 Abbott Res Bv Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US10472426B2 (en) 2010-03-25 2019-11-12 Ucb Biopharma Sprl Disulfide stabilized DVD-Ig molecules
EP2552947A4 (de) 2010-03-26 2013-11-13 Dartmouth College Vista-regulatorisches t-zellen-mediator-protein, vista-bindende wirkstoffe und verwendung davon
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
EP2552479A4 (de) 2010-03-30 2015-03-04 Sinai School Medicine Influenzavirus-impfstoffe und verwendungen davon
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
AU2011239706B2 (en) 2010-04-13 2015-08-20 Celldex Therapeutics Inc. Antibodies that bind human CD27 and uses thereof
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
EP2380909A1 (de) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. An Brustkrebs beteiligtes Protein PTK-7
NZ603226A (en) 2010-04-30 2015-02-27 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
PL2571531T3 (pl) 2010-04-30 2016-12-30 Kompozycje stabilizowanych domen fibronektyny, sposoby i zastosowania
SG185366A1 (en) 2010-05-04 2012-12-28 Merrimack Pharmaceuticals Inc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
MX2012012927A (es) 2010-05-06 2013-05-01 Novartis Ag Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
EP2566892B1 (de) 2010-05-06 2017-12-20 Novartis AG Zusammensetzungen und verfahren zur verwendung von therapeutischen antikörpern gegen ldl-assoziiertes protein 6 (lrp6)
IL208820A0 (en) 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
KR20130065662A (ko) 2010-05-07 2013-06-19 조마 테크놀로지 리미티드 ⅠＬ-1β 관련 병태의 치료 방법
MY161302A (en) 2010-05-14 2017-04-14 Abbvie Inc IL-1 binding proteins
WO2011141823A2 (en) 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
EP2578231B1 (de) 2010-05-28 2022-10-26 Chugai Seiyaku Kabushiki Kaisha Antitumor-t-zellen-reaktionsverstärker
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
EP3459558B1 (de) 2010-06-25 2020-07-29 Aston University Glycoproteine mit fettmobilisierungseigenschaften und therapeutische verwendungen davon
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
AU2011274472B2 (en) 2010-07-09 2017-03-30 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
EP3336225B1 (de) 2010-07-16 2020-02-19 Adimab, LLC Antikörperbibliotheken
CN103108886B (zh) 2010-07-20 2016-08-24 赛法隆澳大利亚控股有限公司 抗il-23杂二聚体特异性抗体
MX339622B (es) 2010-08-02 2016-06-02 Macrogenics Inc Diacuerpos covalentes y sus usos.
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
AU2011288412A1 (en) 2010-08-13 2013-02-21 Medimmune Limited Monomeric polypeptides comprising variant Fc regions and methods of use
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
HRP20220405T1 (hr) 2010-08-19 2022-05-27 Zoetis Belgium S.A. Protutijela protiv ngf i njihova upotreba
SI2606070T1 (sl) 2010-08-20 2017-04-26 Novartis Ag Protitelesa za receptor 3 epidermalnega rastnega faktorja (HER3)
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
EP2608803A4 (de) 2010-08-26 2014-01-15 Abbvie Inc Immunglobuline mit zweifacher variabler domäne und ihre verwendung
WO2012028703A1 (en) 2010-09-02 2012-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of the progression of cancer
EP2614082B1 (de) 2010-09-09 2018-10-03 Pfizer Inc 4-1bb-bindemoleküle
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
EP2616100B1 (de) 2010-09-17 2016-08-31 Compugen Ltd. Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
PT2616090T (pt) 2010-09-17 2023-10-16 Takeda Pharmaceuticals Co Estabilização de imunoglobulinas através de formulação aquosa com histidina em ph fracamente ácido a neutro
ES2719624T3 (es) 2010-09-23 2019-07-11 Prec Biologics Inc Peptidomiméticos de cáncer de colon y de páncreas
US20120077691A1 (en) * 2010-09-24 2012-03-29 Full Spectrum Genetics, Inc. Method of analyzing binding interactions
RS57483B1 (sr) 2010-09-29 2018-10-31 Agensys Inc Konjugati antitela i leka (adc) koji se vezuju za 191p4d12 proteine
SG188666A1 (en) 2010-09-30 2013-05-31 Agency Science Tech & Res Methods and reagents for detection and treatment of esophageal metaplasia
WO2012045703A1 (en) 2010-10-05 2012-04-12 Novartis Ag Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
UA118646C2 (uk) 2010-10-13 2019-02-25 Янссен Байотек, Інк. Виділене антитіло, яке специфіічно зв'язується з онкостатином м (оm) людини
EP2632481A1 (de) 2010-10-25 2013-09-04 Regents Of The University Of Minnesota Therapeutische zusammensetzung zur behandlung eines glioblastoms
US20130337470A1 (en) 2010-10-25 2013-12-19 Biogen Idec Ma Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
NZ610153A (en) 2010-10-29 2014-07-25 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
SI2634194T1 (sl) 2010-10-29 2018-11-30 Perseus Proteomics Inc. Anti-cdh3 protitelo, ki ima visoko kapaciteto internalizacije
EP2635674A4 (de) 2010-11-05 2014-11-05 Transbio Ltd Marker für endothelial-vorläuferzellen und verwendungen davon
US20140093506A1 (en) 2010-11-15 2014-04-03 Marc Buehler Anti-fungal-agents
US20130244907A1 (en) 2010-11-18 2013-09-19 National University Corporation Okayama University Method for preparing b cell which produces human-type antibody
DK2640742T3 (en) 2010-11-19 2018-12-03 Morphosys Ag COLLECTION OF ANTIBODY SEQUENCES AND THEIR APPLICATIONS
EP2643353A1 (de) 2010-11-24 2013-10-02 Novartis AG Multispezifische moleküle
CN103459422A (zh) 2010-11-24 2013-12-18 葛兰素集团有限公司 靶向hgf的多特异性抗原结合蛋白
TWI654203B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
PT2647707T (pt) 2010-11-30 2018-11-15 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de toxicidade
CN103339147A (zh) 2010-12-20 2013-10-02 米迪缪尼有限公司 抗il-18抗体和其用途
US20120275996A1 (en) 2010-12-21 2012-11-01 Abbott Laboratories IL-1 Binding Proteins
US8853365B2 (en) 2010-12-21 2014-10-07 Abbvie Inc. Dual variable domain immunnoglobulins and uses thereof
PT2654790T (pt) 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada
WO2012085113A1 (en) 2010-12-23 2012-06-28 Roche Diagnostics Gmbh Binding agent
CA2817455C (en) 2010-12-23 2019-04-16 F. Hoffmann-La Roche Ag Detection of a polypeptide dimer by a bivalent binding agent
EP2659269B1 (de) 2010-12-23 2016-10-26 Roche Diagniostics GmbH Erkennung von posttranslational modifiziertem polypeptid durch ein bivalentes bindungsmolekül
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
JP2014504503A (ja) 2010-12-28 2014-02-24 ゾーマ テクノロジー リミテッド Ｐｄｚドメインを用いた細胞表面提示
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
EA037071B1 (ru) 2011-01-14 2021-02-02 Юсб Байофарма Срл Молекулы антител, которые связываются с il-17a и il-17f
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
CN103492562B (zh) 2011-02-03 2017-04-05 佐马技术有限公司 用于增强细菌中功能蛋白表达的方法和材料
EP2673299B1 (de) 2011-02-07 2017-05-10 Research Development Foundation Manipulierte immunglobulin-fc-polypeptide
ES2717657T3 (es) 2011-02-15 2019-06-24 Immunogen Inc Métodos para la preparación de conjugados
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
US9624294B2 (en) 2011-03-14 2017-04-18 Cellmid Limited Antibody recognizing N-domain of midkine
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
PL2691155T3 (pl) 2011-03-29 2019-06-28 Immunogen, Inc. Otrzymywanie koniugatu majtansynoidu przeciwciała jednoetapowym sposobem
SG193996A1 (en) 2011-03-29 2013-11-29 Immunogen Inc Preparation of maytansinoid antibody conjugates by a one-step process
DK2698431T3 (da) 2011-03-30 2020-11-30 Chugai Pharmaceutical Co Ltd Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet
WO2012138774A2 (en) 2011-04-04 2012-10-11 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
SG10201603034TA (en) 2011-04-15 2016-05-30 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
JP6104794B2 (ja) 2011-04-18 2017-03-29 国立大学法人 東京大学 抗ｉｔｍ２ａ抗体を用いる癌の診断および治療
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
AU2012245073B2 (en) 2011-04-21 2016-02-11 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
TR201808018T4 (tr) 2011-04-25 2018-06-21 Daiichi Sankyo Co Ltd Anti-B7-H3 antikoru.
BR112013028652A8 (pt) 2011-05-06 2017-12-26 Nvip Pty Ltd Anticorpos anti-fator de crescimento neuronal e métodos para preparação e utilização dos mesmos
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
HRP20211869T1 (hr) 2011-05-06 2022-03-04 Zoetis Services Llc Protutijela protiv faktora rasta živca i postupci za njihovu proizvodnju i uporabu
JP6258194B2 (ja) 2011-05-06 2018-01-10 ネックスヴェット オーストラリア プロプライエタリー リミテッド 抗神経成長因子抗体並びに前記の製造及び使用方法
JP5980202B2 (ja) 2011-05-09 2016-08-31 株式会社ペルセウスプロテオミクス トランスフェリン受容体を特異的に認識できる抗体
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
LT2710033T (lt) 2011-05-17 2021-06-10 The Rockefeller University Žmogaus imunodeficito virusą neutralizuojantys antikūnai ir jų panaudojimo būdai
BR112013029892A2 (pt) 2011-05-21 2016-12-20 Macrogenics Inc polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
WO2012168259A1 (en) 2011-06-06 2012-12-13 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
MX2013014475A (es) 2011-06-10 2014-05-27 Corimmun Gmbh COMPUESTOS DE ENLACE A ß1-ADRENORECEPTOR HUMANO (ß-AR) Y SU USO EN LA MEDICION DE ANTICUERPOS AUTO-ANTI-ß1-AR.
AU2012267732A1 (en) 2011-06-10 2014-01-09 Medimmune Limited Anti-Pseudomonas Psl binding molecules and uses thereof
US9193793B2 (en) 2011-06-13 2015-11-24 Csl Limited Antibodies against G-CSFR and uses thereof
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
BR112013032928A2 (pt) 2011-06-21 2017-01-24 Immunogen Inc "derivados de maitansinoide com ligante de peptídeo e conjugados dos mesmos, composição farmacêutica que os compreende e uso dos mesmos"
PL2726094T3 (pl) 2011-06-28 2017-06-30 Oxford Biotherapeutics Ltd Cel terapeutyczny i diagnostyczny
PL2726508T3 (pl) 2011-06-28 2017-12-29 Oxford Biotherapeutics Ltd Przeciwciała przeciwko cyklazie ADP-rybozylowej 2
US9890218B2 (en) 2011-06-30 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
EP2726503B1 (de) 2011-06-30 2019-09-04 Compugen Ltd. Polypetide und ihre verwendung zur behandlung von autoimmunerkrankungen und infektionen
PL2726099T3 (pl) 2011-07-01 2018-12-31 Novartis Ag Sposób leczenia zaburzeń metabolicznych
MX2014000531A (es) 2011-07-13 2014-12-05 Abbvie Inc Metodos y composiciones para el tratamiento del asma usando anticuerpos anti-il-13.
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
JP2014526886A (ja) 2011-07-15 2014-10-09 モルフォシス・アー・ゲー マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体
CN104023746B (zh) 2011-07-15 2016-08-17 昂考梅德药品有限公司 Rspo结合剂和其应用
EP2735315B1 (de) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Proteinhaltige stabile zubereitung mit argininamid oder valinamid
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
MX2014001019A (es) 2011-07-27 2014-05-13 Glaxo Group Ltd Dominios variables singulares anti-vgf fusionados con dominios de fc.
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
EP2749572A4 (de) 2011-08-23 2015-04-01 Chugai Pharmaceutical Co Ltd Neuer anti-ddr1-antikörper mit antitumoraktivität
EP2751139A1 (de) 2011-08-30 2014-07-09 NVIP Pty Ltd Caninisierte tumornekrosefaktor-antikörper und verfahren zu ihrer verwendung
US20140234903A1 (en) 2011-09-05 2014-08-21 Eth Zurich Biosynthetic gene cluster for the production of peptide/protein analogues
US10018630B2 (en) 2011-09-07 2018-07-10 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
EP2753356B1 (de) 2011-09-09 2021-12-22 Medimmune Limited Anti-siglec-15 antikörper und ihre verwendungen
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
JP6498439B2 (ja) 2011-09-20 2019-04-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
AU2012310880B2 (en) 2011-09-21 2015-12-03 Fujirebio Inc. Antibody against affinity complex
EP2758437B1 (de) 2011-09-22 2020-06-03 Amgen Inc. Cd27l-antigen-bindende proteine
HUE042192T2 (hu) 2011-09-23 2019-06-28 Oncomed Pharm Inc VEGF/DLL4-kötõ ágensek és alkalmazásaik
EP2761066B1 (de) 2011-09-27 2018-12-05 Janssen Biotech, Inc. Auf fibronektin typ iii repeat basierende proteingerüste mit alternativen bindeoberflächen
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EA035018B1 (ru) 2011-09-30 2020-04-17 Тева Фармасьютикал Австралия Пти Лтд. АНТИТЕЛА К TL1a И ИХ ПРИМЕНЕНИЕ
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
CA3186128A1 (en) 2011-09-30 2013-04-04 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting elimination of antigens
MX366269B (es) 2011-09-30 2019-07-04 Chugai Pharmaceutical Co Ltd Biblioteca de moleculas de union dependientes de la concentracion ionica.
KR102239138B1 (ko) 2011-09-30 2021-04-12 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
EP2765192A4 (de) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd Antigenbindendes molekül zur herstellung eines abstands zwischen einem plasma und einem antigen mit einer saccharidkettenrezeptor-bindenden domäne
US9575073B2 (en) 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
CN104080471B (zh) 2011-10-14 2018-08-10 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
CN104203978A (zh) 2011-10-24 2014-12-10 艾伯维股份有限公司 针对硬化蛋白的免疫结合剂
EP2771351B1 (de) 2011-10-28 2017-06-14 Patrys Limited Pat-lm1-epitope und verfahren zu ihrer verwendung
EP3603671A3 (de) 2011-10-28 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Krebstammzellenspezifisches molekül
KR102398736B1 (ko) 2011-10-31 2022-05-16 추가이 세이야쿠 가부시키가이샤 중쇄와 경쇄의 회합이 제어된 항원 결합 분자
EP2773373B1 (de) 2011-11-01 2018-08-22 Bionomics, Inc. Verfahren zur blockierung eines krebsstammzellenwachstums
EP2773665A1 (de) 2011-11-01 2014-09-10 Bionomics, Inc. Antikörper und verfahren zur behandlung von krebs
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
RU2014122602A (ru) 2011-11-04 2015-12-10 Новартис Аг Конструкции на основе белка, родственного липопротеинам низкой плотности, 6(lrp6), и удлинителя полупериода существования
US20140314787A1 (en) 2011-11-08 2014-10-23 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Treatment for neurodegenerative diseases
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
WO2013071233A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detecting infectious agents and a novel virus detected thereby
CA2856216C (en) 2011-11-11 2021-01-12 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
DK2797957T3 (da) 2011-11-23 2019-09-23 Medimmune Llc Bindingsmolekyler specifikke for her3 og anvendelser deraf
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
IN2014CN04373A (de) 2011-12-05 2015-09-04 Novartis Ag
EA202092280A3 (ru) 2011-12-05 2021-09-30 Новартис Аг Антитела к рецептору эпидермального фактора роста 3 (her3)
CA2855570A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
EP2791173B1 (de) 2011-12-14 2020-07-29 AbbVie Deutschland GmbH & Co. KG Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
AU2012356170B2 (en) 2011-12-21 2016-06-16 Novartis Ag Compositions and methods for antibodies targeting Factor P
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
WO2013102825A1 (en) 2012-01-02 2013-07-11 Novartis Ag Cdcp1 and breast cancer
WO2013104798A1 (en) 2012-01-12 2013-07-18 Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences Modulators of immune responses
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
CN107880124B (zh) 2012-01-27 2021-08-13 艾伯维德国有限责任两合公司 用于诊断和治疗与神经突变性相关的疾病的组合物和方法
CA2848985A1 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
KR102091297B1 (ko) 2012-02-03 2020-03-20 에프. 호프만-라 로슈 아게 항원-형질감염된 t 세포와 함께 사용되는 이중특이적 항체 분자 및 의약에서의 이들의 용도
MX360772B (es) 2012-02-06 2018-11-15 Inhibrx Inc Anticuerpos cd47 y metodos de uso de los mismos.
US20150210763A1 (en) 2012-02-09 2015-07-30 Chugai Seiyaku Kabushiki Kaisha MODIFIED Fc REGION OF ANTIBODY
CN108324943B (zh) 2012-02-10 2024-03-08 思进股份有限公司 Cd30+癌症的检测和治疗
EP2812357B1 (de) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Einzelketten-antikörper und andere heteromultimere
PL2814844T3 (pl) 2012-02-15 2017-12-29 Novo Nordisk A/S Przeciwciała wiążące i blokujące receptor aktywujący wykazujący ekspresję na komórkach szpikowych -1 (trem-1)
RS57827B1 (sr) 2012-02-15 2018-12-31 Novo Nordisk As Antitela koja vezuju protein 1 prepoznavanja peptidoglikana
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
RU2736349C2 (ru) 2012-02-24 2020-11-16 Чугаи Сейяку Кабусики Кайся АНТИГЕНСВЯЗЫВАЮЩАЯ МОЛЕКУЛА ДЛЯ УСКОРЕНИЯ ИСЧЕЗНОВЕНИЯ АНТИГЕНА ЧЕРЕЗ FcγRIIB
UA121844C2 (uk) 2012-03-15 2020-08-10 Янссен Байотек, Інк. Людське антитіло до cd27, спосіб його одержання та застосування
EP2825557B1 (de) 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Manipuliertes lösliches monomeres fc
CA2866185C (en) 2012-03-23 2021-04-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pathogenic phlebovirus isolates and compositions and methods of use
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
RU2014139546A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Методы прогнозирования, диагностики и лечения идиопатического легочного фиброза
EP2832856A4 (de) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd Anti-lamp5-antikörper und verwendung davon
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
CN104321430A (zh) 2012-03-30 2015-01-28 第一三共株式会社 新颖的抗-siglec-15抗体
CA2869704A1 (en) 2012-04-04 2013-10-10 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (pcadherin) antibody
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
CN104334724B (zh) 2012-04-09 2020-09-01 第一三共株式会社 抗-fgfr2抗体
WO2013160879A1 (en) 2012-04-27 2013-10-31 Daiichi Sankyo Company, Limited Anti-robo4-antibody
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
AU2013262934B2 (en) 2012-05-14 2018-02-01 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
JP6122948B2 (ja) 2012-05-15 2017-04-26 モルフォテック， インコーポレイテッド 胃癌の治療のための方法
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
BR112014029274B1 (pt) 2012-05-24 2022-02-15 Mountgate Innotech (Hk) Limited Anticorpo isolado, composição farmacêutica, uso do anticorpo, e, kit para tratar infecção rábica
JPWO2013180201A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 会合化した抗原を消失させる抗原結合分子
CA2874721A1 (en) 2012-05-30 2013-12-05 Tomoyuki Igawa Target tissue-specific antigen-binding molecule
EP2858673A4 (de) 2012-06-06 2016-06-22 Oncomed Pharm Inc Bindungsmittel zur modulation des hippo-pfads und verwendungen davon
CN104364264B (zh) 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
EP2862875B1 (de) 2012-06-14 2023-09-06 Chugai Seiyaku Kabushiki Kaisha Antigenbindendes molekül mit modifizierter fc-region
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
MX2014016038A (es) 2012-06-22 2015-08-14 Cytomx Therapeutics Inc Anticuerpos de reaccion cruzada anti - jagged 1 / jagged 2, anticuerpos anti - jagged activables y metodos para uso de los mismos.
CN104619722B (zh) 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
KR20150023889A (ko) 2012-06-27 2015-03-05 에프. 호프만-라 로슈 아게 2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
CA2871386A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
WO2014001557A1 (en) 2012-06-28 2014-01-03 Ucb Pharma S.A. A method for identifying compounds of therapeutic interest
WO2014001482A1 (en) 2012-06-29 2014-01-03 Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014006114A1 (en) 2012-07-05 2014-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
TW201402608A (zh) 2012-07-12 2014-01-16 Abbvie Inc Ｉｌ－１結合蛋白質
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014020140A1 (en) 2012-08-02 2014-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of transferrin receptor antagonist for the treatment of thalassemia
EP2887965A1 (de) 2012-08-22 2015-07-01 ImmunoGen, Inc. Zytotoxische benzodiazepin-derivate
EP2887959B1 (de) 2012-08-23 2018-12-19 Agensys, Inc. An 158p1d7-proteine bindende antikörper-wirkstoffkonjugate
TWI766493B (zh) 2012-08-24 2022-06-01 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
NZ630433A (en) 2012-08-31 2017-10-27 Immunogen Inc Antibodies and uses thereof to detect folate receptor 1
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
CN109793893B (zh) 2012-09-07 2023-05-26 达特茅斯大学理事会 用于诊断和治疗癌症的vista调节剂
US10689705B2 (en) 2012-09-27 2020-06-23 Chugai Seiyaku Kabushiki Kaisha FGFR3 fusion gene and pharmaceutical drug targeting same
WO2014055073A1 (en) 2012-10-03 2014-04-10 Philogen S.P.A. Antigens associated with inflammatory bowel disease
NO2760138T3 (de) 2012-10-01 2018-08-04
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
MX359599B (es) 2012-10-04 2018-09-12 Immunogen Inc Uso de una membrana de pvdf para purificar conjugados de agentes de unión celular y agentes citotóxicos.
LT2907824T (lt) 2012-10-11 2018-06-11 Daiichi Sankyo Company, Limited Antikūno-vaisto konjugatas
CA2887528C (en) 2012-10-12 2023-08-29 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
BR112015008347B1 (pt) 2012-10-15 2023-12-26 Medimmune Limited Molécula de anticorpo, uso de dita molécula de anticorpo, composição para uso no tratamento de uma doença associada com betaamilóide, uso de uma composição, ácido nucleico, célula hospedeira e método para produção de uma molécula de anticorpo
JP6461804B2 (ja) 2012-10-18 2019-01-30 ザ ロックフェラー ユニバーシティー 広域中和抗ｈｉｖ抗体
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
WO2014071282A1 (en) 2012-11-05 2014-05-08 Genzyme Corporation Compositions and methods for treating proteinopathies
EP2918603B1 (de) 2012-11-08 2018-08-29 University of Miyazaki Zur spezifischen erkennung eines transferrin-rezeptors fähiger antikörper
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
PT3447069T (pt) 2012-11-21 2020-11-13 Janssen Biotech Inc Anticorpos biespecíficos de egfr/c-met
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
MX368067B (es) 2012-12-05 2019-09-18 Novartis Ag Composiciones y métodos para dirigir anticuerpos a la eritropoyetina (epo).
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
SI2928923T1 (sl) 2012-12-10 2020-03-31 Biogen Ma Inc. Protitelesa proti antigenu 2 dendritičnih celic v krvi in njihova uporaba
MX2015007755A (es) 2012-12-18 2016-01-14 Icahn School Med Mount Sinai Vacunas contra virus de la influenza y sus usos.
BR112015013861A2 (pt) 2012-12-18 2017-07-11 Novartis Ag composições e métodos para proteínas de ação prolongada
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
RU2691428C2 (ru) 2012-12-21 2019-06-13 МЕДИММЬЮН, ЭлЭлСи Антитела к h7cr
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
AU2013202668B2 (en) 2012-12-24 2014-12-18 Adelaide Research & Innovation Pty Ltd Inhibition of cancer growth and metastasis
WO2014104165A1 (ja) 2012-12-27 2014-07-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
AU2013370171B2 (en) 2012-12-28 2018-09-13 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
AU2014213009B2 (en) 2013-02-01 2019-01-03 Kira Biotech Pty Limited Anti-CD83 antibodies and use thereof
EP4137518A1 (de) 2013-02-06 2023-02-22 Inhibrx, Inc. Nicht-plättchen-depletierende und nicht-erythrozyten-depletierende cd47-antikörpern und verfahren zur verwendung davon
WO2014121325A1 (en) 2013-02-07 2014-08-14 Csl Limited Il-11r binding proteins and uses thereof
US9193788B2 (en) 2013-02-08 2015-11-24 Novartis Ag Anti-IL-17A antibodies and their uses
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
JP6494533B2 (ja) 2013-02-28 2019-04-03 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
CA2902068C (en) 2013-02-28 2023-10-03 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
MX2015012824A (es) 2013-03-14 2016-06-24 Abbott Lab Antigenos recombinantes ns3 del vhc y mutantes de los mismos para la deteccion mejorada de anticuerpos.
AU2014229549B2 (en) 2013-03-14 2018-11-01 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
CN113549148A (zh) 2013-03-14 2021-10-26 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
EP2970479B1 (de) 2013-03-14 2019-04-24 Novartis AG Antikörper gegen notch 3
EP2968526A4 (de) 2013-03-14 2016-11-09 Abbott Lab Hcv-antigen-antikörper-kombinationstest sowie verfahren und zusammensetzungen zur verwendung darin
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN105121470A (zh) 2013-03-15 2015-12-02 艾伯维生物技术有限公司 抗cd25抗体及其用途
SG10201707633VA (en) 2013-03-15 2017-11-29 Abbvie Deutschland Anti-egfr antibody drug conjugate formulations
MX368665B (es) 2013-03-15 2019-10-10 Abbvie Biotherapeutics Inc Variantes de fc.
JP2016515120A (ja) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
CN105358575B (zh) 2013-03-15 2020-09-22 詹森生物科技公司 干扰素α和ω抗体拮抗剂
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
WO2014152199A1 (en) 2013-03-15 2014-09-25 Abbvie Inc. Antibody drug conjugate (adc) purification
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
CN105377892A (zh) 2013-03-15 2016-03-02 艾伯维生物技术有限公司 抗cd25抗体及其用途
RS57840B1 (sr) 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
EP4285988A3 (de) 2013-03-27 2024-03-06 Cedars-Sinai Medical Center Behandlung von fibrose durch tl1a-hemmung
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
US9863953B2 (en) 2013-05-16 2018-01-09 Kyoto University Method for determining prognosis of cancer
AU2014268298B2 (en) 2013-05-24 2019-01-17 Medlmmune, Llc Anti-B7-H5 antibodies and their uses
JP6243521B2 (ja) 2013-05-30 2017-12-06 キニクサ ファーマシューティカルズ， リミテッド オンコスタチンｍ受容体抗原結合タンパク質
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
ES2891755T3 (es) 2013-06-06 2022-01-31 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AU2014299916A1 (en) 2013-06-24 2015-12-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent comprising humanized anti-Epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
EP3013422A1 (de) 2013-06-28 2016-05-04 Amgen Inc. Verfahren zur behandlung von homozygoter familiärer hypercholesterolämie
EP3022295A4 (de) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signatur des tl1a (tnfsf15)-signalweges
EP3027220A1 (de) 2013-08-01 2016-06-08 Agensys, Inc. An cd37-proteine bindende antikörper-wirkstoffkonjugate (adc)
TWI623551B (zh) 2013-08-02 2018-05-11 輝瑞大藥廠 抗ｃｘｃｒ４抗體及抗體－藥物結合物
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
CA2918300A1 (en) 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
US10077304B2 (en) 2013-08-14 2018-09-18 The Governing Council Of The University Of Toronto Antibodies against frizzled receptor
DK3036320T4 (da) 2013-08-19 2024-05-06 Biogen Ma Inc Styring af proteinglycosylering ved hjælp af dyrkningsmedietilsætning og cellekulturprocesparametre
KR20160054501A (ko) 2013-08-26 2016-05-16 맵백스 테라퓨틱스, 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
SI3038650T1 (sl) 2013-08-30 2021-11-30 Immunogen, Inc. Protitelesa in preiskave za odkrivanje folatnega receptorja 1
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
JP6552412B2 (ja) 2013-09-05 2019-07-31 国立大学法人 宮崎大学 ヒトインテグリンａ６ｂ４と特異的に反応する抗体
TWI673063B (zh) 2013-09-20 2019-10-01 日商中外製藥股份有限公司 抗蛋白ｃ抗體之出血性疾病的治療
HUE057005T2 (hu) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc Oszlopon történõ vírusinaktiváló eljárások
MX2016003616A (es) 2013-09-27 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir heteromultimeros de polipeptidos.
CA2925897A1 (en) 2013-09-30 2015-04-02 Daiichi Sankyo Company, Limited Anti-lps o11 antibody
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3733244A1 (de) 2013-10-02 2020-11-04 Medlmmune, LLC Neutralisierende antiinflueanza-a-virus-antikörper und verwendungen davon
JP6509735B2 (ja) 2013-10-08 2019-05-08 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
EP3055332B1 (de) 2013-10-08 2019-09-25 ImmunoGen, Inc. Dosierplan für anti-folr1-immunokonjugate
KR20160067966A (ko) 2013-10-14 2016-06-14 얀센 바이오테크 인코포레이티드 시스테인 조작된 피브로넥틴 iii형 도메인 결합 분자
AU2014342528A1 (en) 2013-10-28 2016-04-28 Dots Technology Corp. Allergen detection
US9840555B2 (en) 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
HUE058272T2 (hu) 2013-11-06 2022-07-28 Janssen Biotech Inc Anti-CCL17 antitestek
US20160280787A1 (en) 2013-11-11 2016-09-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
US9803008B2 (en) 2013-11-28 2017-10-31 Csl Limited Method of treating diabetic nephropathy by administering antibodies to vascular endothelial growth factor B (VEGF-B)
KR20220142539A (ko) 2013-12-04 2022-10-21 추가이 세이야쿠 가부시키가이샤 화합물의 농도에 따라 항원 결합능이 변화되는 항원 결합 분자 및 그의 라이브러리
US9944693B2 (en) 2013-12-08 2018-04-17 Peptcell Limited HIV antigens and antibodies and compositions, uses and methods thereof
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
BR112016014099A2 (pt) 2013-12-18 2017-10-10 B Creative Sweden Ab método de tratamento de feridas
JP2017500017A (ja) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
PL3712174T3 (pl) 2013-12-24 2022-07-04 Janssen Pharmaceutica Nv Przeciwciała i fragmenty anty-vista
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
HUE042512T2 (hu) 2013-12-25 2019-07-29 Daiichi Sankyo Co Ltd Anti-trop2 antitest-gyógyszer konjugátum
CN106029682B (zh) 2013-12-27 2021-04-13 中外制药株式会社 等电点低的抗体的纯化方法
EP3581179A1 (de) 2013-12-27 2019-12-18 Chugai Seiyaku Kabushiki Kaisha Mutantes fgfr-gatekeeper-gen und dagegen gerichteter wirkstoff
HRP20211848T1 (hr) 2014-01-31 2022-03-04 Daiichi Sankyo Company, Limited Anti-her2 antitijelo-lijek konjugat
JP6619745B2 (ja) 2014-02-20 2019-12-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体成分ｃ５抗体
EP3110845A1 (de) 2014-02-27 2017-01-04 Allergan, Inc. Komplementfaktor-bb-antikörper
EP3122757B1 (de) 2014-02-28 2023-09-06 Hangzhou Dac Biotech Co., Ltd Geladene linker und deren verwendungen zur konjugation
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
EP3122869B2 (de) 2014-03-24 2022-08-10 Biogen MA Inc. Verfahren zur überwindung von glutamindeprivation bei einer säugetierzellkultur
WO2015150900A2 (en) 2014-03-31 2015-10-08 Debiopharm International Sa Fgfr fusions
JP6614582B2 (ja) 2014-04-04 2019-12-04 バイオノミクス インコーポレイテッド Ｌｇｒ５に結合するヒト化抗体
SG11201609178SA (en) 2014-04-08 2016-12-29 Medimmune Llc Binding molecules specific for il-21 and uses thereof
KR102239413B1 (ko) 2014-04-10 2021-04-12 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
KR20160143808A (ko) 2014-04-11 2016-12-14 메디뮨 엘엘씨 이중특이적 her2 항체
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
EP3148567A4 (de) 2014-04-25 2018-01-10 The Brigham and Women's Hospital, Inc. Verfahren zur manipulation von alpha-fetoprotein (afp)
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
WO2015175874A2 (en) 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
CN108064242B (zh) 2014-05-28 2022-10-21 阿吉纳斯公司 抗gitr抗体和其使用方法
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
CA3121083C (en) 2014-06-04 2023-08-15 Biontech Research And Development, Inc. Human monoclonal antibodies to ganglioside gd2
DK3151921T3 (da) 2014-06-06 2019-12-02 Bristol Myers Squibb Co Antistoffer mod glucocorticoid-induceret tumornekrosefaktor- receptorer (gitr) og anvendelser deraf
MX2016016310A (es) 2014-06-11 2017-10-20 A Green Kathy Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
US20170137824A1 (en) 2014-06-13 2017-05-18 Indranil BANERJEE New treatment against influenza virus
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
WO2015198202A1 (en) 2014-06-23 2015-12-30 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
EP3161001A2 (de) 2014-06-25 2017-05-03 Novartis AG Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CN106659772B (zh) 2014-06-26 2021-08-31 耶鲁大学 在疾病和紊乱的治疗中调节肾酶的组合物和方法
EP3164129A1 (de) 2014-07-01 2017-05-10 Friedrich Miescher Institute for Biomedical Research Kombination eines brafv600e-hemmers und mertk-hemmers zur melanombehandlung
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
CU24453B1 (es) 2014-08-07 2019-11-04 Novartis Ag Anticuerpos anti proteína similar a angiopoyetina 4
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
US20170362304A1 (en) 2014-08-20 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
US9381256B2 (en) 2014-09-03 2016-07-05 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
MA54254A (fr) 2014-09-03 2021-09-22 Immunogen Inc Dérivés de benzodiazépine cytotoxique
EP3191136A1 (de) 2014-09-08 2017-07-19 Michaela Arndt Konstrukt zur verabreichung eines moleküls in das zytoplasma einer zelle
CR20170086A (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-cd38
EP3197557A1 (de) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats und brustrkrebs
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
NZ730247A (en) 2014-10-01 2022-11-25 Medimmune Ltd Antibodies to ticagrelor and methods of use
WO2016054598A2 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
MA41685A (fr) 2014-10-17 2017-08-22 Biogen Ma Inc Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
EP3209695A4 (de) 2014-10-23 2018-05-30 DendroCyte BioTech Pty Ltd Cd83-bindende proteine und verwendungen davon
WO2016061632A1 (en) 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
US10738078B2 (en) 2014-11-03 2020-08-11 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
MY191423A (en) 2014-11-10 2022-06-27 Medimmune Ltd Binding molecules specific for cd73 and uses thereof
US20160129108A1 (en) 2014-11-11 2016-05-12 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2016077526A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN107406503B (zh) 2014-11-18 2021-07-16 詹森药业有限公司 Cd47抗体、方法和用途
WO2016079219A1 (en) 2014-11-19 2016-05-26 Koninklijke Philips N.V. Diagnostic method employing hnl
MA40934A (fr) 2014-11-19 2017-09-27 Immunogen Inc Procédé de préparation de conjugués agent de liaison cellulaire-agent cytotoxique
SI3221363T1 (sl) 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Protitelesa proti CD73 in njihova uporaba
US11033637B2 (en) 2014-11-21 2021-06-15 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
EP3227332B1 (de) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispezifische antikörper
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
AU2015360694B2 (en) 2014-12-08 2021-10-14 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
EP3735990A1 (de) 2014-12-09 2020-11-11 Abbvie Inc. Antikörper-wirkstoff-konjugate mit zelldurchlässigen bcl-xl-inhibitoren
MX2017007629A (es) 2014-12-09 2018-05-17 Abbvie Inc Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen.
SG11201704752WA (en) 2014-12-11 2017-07-28 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
PL3233912T3 (pl) 2014-12-19 2021-12-27 Regenesance B.V. Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania
US10940212B2 (en) 2014-12-19 2021-03-09 Monash University IL-21 agonist antibodies and methods of treatment using same
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CA2972048C (en) 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
TN2017000267A1 (en) 2014-12-23 2018-10-19 Bristol Myers Squibb Co Antibodies to tigit
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
CA2973978A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
EP3253793A4 (de) 2015-02-02 2018-11-14 i2 Pharmaceuticals, Inc. Leichtkettige anti-surrogate-antikörper
WO2016128349A1 (en) 2015-02-09 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to glycoprotein (gp) of ebolavirus and uses for the treatment and diagnosis of ebola virus infection
WO2016130516A1 (en) 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
RU2730590C2 (ru) 2015-02-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Композиция для лечения заболеваний, связанных с ил-6
EP3265123B1 (de) 2015-03-03 2022-10-26 Kymab Limited Antikörper, verwendungen und verfahren
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
WO2016149088A1 (en) 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
SG11201707538XA (en) 2015-03-17 2017-10-30 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
WO2016153978A1 (en) 2015-03-20 2016-09-29 Bristol-Myers Squibb Company Use of dextran to enhance protein purification by affinity chromatography
WO2016153983A1 (en) 2015-03-20 2016-09-29 Bristol-Myers Squibb Company Use of dextran for protein purification
WO2016151558A1 (en) 2015-03-25 2016-09-29 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
ES2721781T3 (es) 2015-03-25 2019-08-05 Alexion Pharma Inc Un método para medir la actividad proteasa de C3 y C5 convertasa de la vía de complemento alternativa
ES2904573T3 (es) 2015-03-27 2022-04-05 Univ Southern California Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos
MY190209A (en) 2015-03-31 2022-04-05 Medimmune Ltd A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
US10814012B2 (en) 2015-04-29 2020-10-27 University Of South Australia Compositions and methods for administering antibodies
WO2016177651A1 (en) 2015-05-01 2016-11-10 Medimmune Limited Novel phage display library, members thereof and uses of the same
CA2985138A1 (en) 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen binding fibronectin type iii domains
EP3291836A4 (de) 2015-05-06 2018-11-14 Janssen Biotech, Inc. Bispezifische bindemittel für prostataspezifisches membranantigen (psma) und verwendungen davon
CA2984794A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
AU2016263198C1 (en) 2015-05-15 2023-10-05 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3095465A1 (de) 2015-05-19 2016-11-23 U3 Pharma GmbH Kombination von fgfr4-inhibitor und gallensäurekomplexbildner
KR102602754B1 (ko) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
CN113940996A (zh) 2015-05-27 2022-01-18 Ucb生物制药私人有限公司 用于治疗神经***疾病的方法
HUE061253T2 (hu) 2015-05-29 2023-06-28 Bristol Myers Squibb Co Antitestek OX40 ellen és azok felhasználásai
KR20230028478A (ko) 2015-05-29 2023-02-28 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법
SI3303395T1 (sl) 2015-05-29 2020-03-31 Abbvie Inc. Protitelesa proti CD40 in njihove uporabe
AU2016270474A1 (en) 2015-06-04 2018-01-04 University Of Southern California Lym-1 and Lym-2 targeted CAR cell immunotherapy
BR112017021484A2 (pt) 2015-06-05 2018-07-03 Novartis Ag anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
EP3307772B1 (de) 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta-3-spezifische antikörper und verfahren sowie verwendungen davon
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
MX2018000265A (es) 2015-06-22 2018-05-23 Janssen Biotech Inc Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina.
US20160376373A1 (en) 2015-06-24 2016-12-29 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP3313882B1 (de) 2015-06-24 2020-03-11 Janssen Pharmaceutica NV Anti-vista-antikörper und -fragmente
PT3313884T (pt) 2015-06-29 2021-02-25 Immunogen Inc Anticorpos anti-cd123 e conjugados e derivados dos mesmos
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
WO2017021893A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
CN114605549A (zh) 2015-08-05 2022-06-10 詹森生物科技公司 抗cd154抗体及其使用方法
WO2017031353A1 (en) 2015-08-19 2017-02-23 Rutgers, The State University Of New Jersey Novel methods of generating antibodies
EP3344656A1 (de) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1-antikörper und verfahren zur verwendung davon
JP6516925B2 (ja) 2015-09-09 2019-05-22 ノバルティス アーゲー 胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合性抗体および抗体を使用する方法
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
WO2017044859A1 (en) * 2015-09-10 2017-03-16 Affigen, Inc. Sequencing-directed selection of tumor theranostics
RU2749865C2 (ru) 2015-09-17 2021-06-17 Иммьюноджен, Инк. Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
MY191756A (en) 2015-09-23 2022-07-14 Genentech Inc Optimized variants of anti-vegf antibodies
CN109310744A (zh) 2015-09-23 2019-02-05 赛通免疫有限责任公司 用于免疫治疗的flt3定向car细胞
IL288784B2 (en) 2015-09-24 2023-10-01 Daiichi Sankyo Co Ltd Antibodies against GARP, nucleotides encoding them, and vectors, cells and preparations containing them, methods for their preparation and uses thereof
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
MY196646A (en) 2015-09-30 2023-04-27 Janssen Biotech Inc Agonistic Antibodies Specifically Binding Human CD40 And Methods of use
AU2016347471B2 (en) 2015-10-27 2023-08-03 UCB Biopharma SRL Methods of treatment using anti-IL-17A/F antibodies
EP3368566A1 (de) 2015-10-28 2018-09-05 Friedrich Miescher Institute for Biomedical Research Tenascin-w und gallengangkrebs
KR20180067693A (ko) 2015-11-03 2018-06-20 얀센 바이오테크 인코포레이티드 항-cd38 항체의 피하 제제 및 이의 용도
MX2018005550A (es) 2015-11-03 2019-07-18 Janssen Biotech Inc Anticuerpos que se unen especificamente a tim-3 y sus usos.
EP3374398B1 (de) 2015-11-10 2020-03-18 MedImmune, LLC Für asct2 spezifische bindemoleküle und verwendungen davon
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
JP6925278B2 (ja) 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
EP3383904A4 (de) 2015-11-19 2019-12-04 Zeling Cai Ctla-4-antikörper und verwendungen davon
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
JP2019500327A (ja) 2015-11-30 2019-01-10 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
PT3383920T (pt) 2015-11-30 2024-04-15 The Regents Of The Univ Of California Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
WO2017095808A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
WO2017095875A1 (en) 2015-11-30 2017-06-08 Bristol-Myers Squibb Company Anti human ip-10 antibodies and their uses
ES2861449T3 (es) 2015-12-02 2021-10-06 Stcube & Co Inc Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
EP3383908A1 (de) 2015-12-02 2018-10-10 Stsciences, Inc. Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator)
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
US10829562B2 (en) 2015-12-10 2020-11-10 Katholieke Universiteit Leuven Haemorrhagic disorder due to ventricular assist device
US20180355043A1 (en) 2015-12-17 2018-12-13 Janssen Biotech, Inc. Antibodies Specifically Binding HLA-DR and Their Uses
TW201731872A (zh) 2015-12-18 2017-09-16 諾華公司 標靶CD32b之抗體及其使用方法
EP3184544A1 (de) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein-v-inhibitoren zur verwendung als koagulansien
JP7308505B2 (ja) 2016-01-08 2023-07-14 マキシオン セラピューティクス リミテッド 多様性を変化させた足場ドメインを有する結合メンバー
JP2019504064A (ja) 2016-01-08 2019-02-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型ミオスタチン抗体およびその使用方法
WO2017121880A1 (en) 2016-01-15 2017-07-20 Philogen S.P.A Intestinal antigens for pharmacodelivery applications
US20210198368A1 (en) 2016-01-21 2021-07-01 Novartis Ag Multispecific molecules targeting cll-1
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
SG11201806478PA (en) 2016-02-05 2018-08-30 Immunogen Inc Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
GB201602413D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Method
TWI756204B (zh) 2016-02-12 2022-03-01 比利時商楊森製藥公司 抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法
MA44242A (fr) 2016-02-16 2018-12-26 Regeneron Pharma Animaux non humains ayant un gène de kynuréninase mutant
SG11201807677YA (en) 2016-03-04 2018-10-30 Univ Rockefeller Antibodies to cd40 with enhanced agonist activity
IL295230A (en) 2016-03-04 2022-10-01 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
RU2756109C2 (ru) 2016-03-10 2021-09-28 Виела Байо, Инк. Связывающие ilt7 молекулы и способы их применения
CN109153713B (zh) 2016-03-10 2022-12-27 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
SG10202007025PA (en) 2016-03-14 2020-08-28 Chugai Pharmaceutical Co Ltd Cell injury inducing therapeutic drug for use in cancer therapy
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
WO2017161071A1 (en) 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions
WO2017161067A1 (en) 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions
ES2836349T3 (es) 2016-03-17 2021-06-24 Tillotts Pharma Ag Anticuerpos anti-TNF-alfa y fragmentos funcionales de los mismos
SG11201808041UA (en) 2016-03-17 2018-10-30 Numab Innovation Ag ANTI-TNFa-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
EP3430042B1 (de) 2016-03-17 2023-05-24 Numab Innovation AG Anti-tnf-alpha-antikörper und funktionale fragmente davon
MA43715A (fr) 2016-03-17 2018-11-28 Numab Innovation Ag Anticorps anti-tnf et fragments fonctionnels correspondants
ES2843974T3 (es) 2016-03-17 2021-07-21 Tillotts Pharma Ag Anticuerpos anti-TNF alfa y fragmentos funcionales de los mismos
KR20220153109A (ko) 2016-03-17 2022-11-17 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
CA3019164A1 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
CN117562992A (zh) 2016-04-15 2024-02-20 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
CA3021328A1 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
AU2017264578A1 (en) 2016-05-09 2019-01-03 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
PT3626273T (pt) 2016-05-17 2021-03-09 Abbvie Inc Conjugados de fármacos com anticorpo anti-cmet e métodos para o seu uso
WO2017205465A2 (en) 2016-05-24 2017-11-30 Griswold Karl Edwin Antibodies and methods of making same
AU2017271588B2 (en) 2016-05-27 2022-01-20 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof
JP2019523221A (ja) 2016-05-27 2019-08-22 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ｃｄ４０抗体とその使用
WO2017205745A1 (en) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
US10925932B2 (en) 2016-06-03 2021-02-23 Janssen Biotech, Inc. Serum albumin-binding fibronectin type III domains
LT3458479T (lt) 2016-06-08 2021-02-25 Abbvie Inc. Anti-b7-h3 antikūnai ir antikūnų vaisto konjugatai
IL301468A (en) 2016-06-13 2023-05-01 Scholar Rock Inc Use of myostatin inhibitors and combined treatments
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CA3027651A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
EP3471750A4 (de) 2016-06-21 2020-02-26 Janssen Biotech, Inc. Cysteinmanipulierte fibronectin-typ-iii-domänenbindungsmoleküle
EP3474895A1 (de) 2016-06-28 2019-05-01 UMC Utrecht Holding B.V. Behandlung von ige-vermittelten erkrankungen mit spezifisch cd38 bindenden antikörpern
WO2018009499A1 (en) 2016-07-06 2018-01-11 Celgene Corporation Antibodies with low immunogenicity and uses thereof
US20180024132A1 (en) 2016-07-07 2018-01-25 Berg Llc Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
EP3484920A2 (de) 2016-07-14 2019-05-22 Bristol-Myers Squibb Company Antikörper gegen tim3 und verwendungen davon
AU2017296237A1 (en) 2016-07-15 2019-01-03 Poseida Therapeutics, Inc. Chimeric antigen receptors (CARS) specific for MUC1 and methods for their use
MX2019000643A (es) 2016-07-15 2019-06-13 Poseida Therapeutics Inc Receptores de antigenos quimericos y metodos de uso.
EP3487506A1 (de) 2016-07-20 2019-05-29 Hybrigenics SA Kombinationen von inecalcitol mit einem anti-cd38-mittel und deren verwendungen zur behandlung von krebs
US10941200B2 (en) 2016-07-22 2021-03-09 Deutsches Zentrum Für Neurodegenerative Erkrankungen Ev TREM2 cleavage modulators and uses thereof
EP3487880A1 (de) 2016-07-25 2019-05-29 Biogen MA Inc. Anti-hspa5(grp78)-antikörper und verwendungen davon
US11186634B2 (en) 2016-07-29 2021-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies targeting tumor associated macrophages and uses thereof
CA3031735A1 (en) 2016-08-05 2018-02-08 Medimmune, Llc Anti-o2 antibodies and uses thereof
KR102554331B1 (ko) 2016-08-12 2023-07-10 얀센 바이오테크 인코포레이티드 향상된 효능적 활성을 갖는 Fc 조작된 항-TNFR 수퍼패밀리 구성원 항체 및 그의 사용 방법
EP3497112A1 (de) 2016-08-12 2019-06-19 Bristol-Myers Squibb Company Verfahren zur aufreinigung von proteinen
SG11201900746RA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
BR112019004711A2 (pt) 2016-09-14 2019-05-28 Janssen Biotech Inc receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
SG10201914120XA (en) 2016-09-14 2020-03-30 Abbvie Biotherapeutics Inc Anti-pd-1(cd279) antibodies
JP7051826B2 (ja) 2016-09-23 2022-04-11 シーエスエル、リミテッド 凝固因子結合タンパク質及びその使用
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
US20180094052A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibody
AU2017339858B2 (en) 2016-10-03 2022-02-17 Abbott Laboratories Improved methods of assessing GFAP status in patient samples
WO2018066626A1 (ja) 2016-10-07 2018-04-12 第一三共株式会社 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
CA3040189A1 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
EP3312290A1 (de) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Zellulärer vamp-spaltungstest
EA201990895A1 (ru) 2016-10-19 2019-10-31 Антитела к о1 и варианты их применения
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
CN110300600A (zh) 2016-11-02 2019-10-01 伊缪诺金公司 利用抗体-药物缀合物和parp抑制剂的组合治疗
WO2018083240A1 (en) 2016-11-03 2018-05-11 Roche Diagnostics Gmbh Novel anti-py796-ddr1 antibodies
WO2018083238A1 (en) 2016-11-03 2018-05-11 Roche Diagnostics Gmbh Novel anti-py792-ddr1 antibodies
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
WO2018083237A1 (en) 2016-11-03 2018-05-11 Roche Diagnostics Operations Inc. Novel anti-py520-ddr1 antibodies
WO2018083235A1 (en) 2016-11-03 2018-05-11 Roche Diagnostics Gmbh Novel anti-py513-ddr1 antibodies
CA3042989A1 (en) 2016-11-07 2018-05-11 Junho Chung Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
CA3043146C (en) 2016-11-09 2021-11-23 Philogen S.P.A. Il2 and tnf mutant immunoconjugates
EP3538549A1 (de) 2016-11-10 2019-09-18 iOmx Therapeutics AG Or10h1-antigen-binding proteine und verwendungen davon
KR20220147720A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
WO2018093841A1 (en) 2016-11-16 2018-05-24 Janssen Biotech, Inc. Method of treating psoriasis with anti-il-23 specific antibody
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR102477612B1 (ko) 2016-11-21 2022-12-14 쿠레아브 게엠베하 항-gp73　항체　및　면역접합체
JP7227146B2 (ja) 2016-11-23 2023-02-21 バイオベラティブ セラピューティクス インコーポレイテッド 凝固第ｉｘ因子および凝固第ｘ因子に結合する二重特異性抗体
KR102533814B1 (ko) 2016-11-28 2023-05-19 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
IL266918B2 (en) 2016-12-07 2024-03-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
EP3554535A4 (de) 2016-12-14 2020-10-21 Janssen Biotech, Inc. Pd-l1-bindende fibronectin-typ iii-domänen
EP3932432A1 (de) 2016-12-14 2022-01-05 Janssen Biotech, Inc. Cd8a-bindende fibronectin-typ-iii-domänen
EP3554561B1 (de) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137-bindende fibronectin-typ-iii-domänen
RS60664B1 (sr) 2016-12-15 2020-09-30 Abbvie Biotherapeutics Inc Anti-ox40 antitela i njihove upotrebe
SG10202108135VA (en) 2016-12-16 2021-09-29 Merck Patent Gmbh Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
CA3048174A1 (en) 2016-12-22 2018-06-28 Daiichi Sankyo Company, Limited Anti-cd3 antibody and molecules comprising the antibody
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
FI3565592T3 (fi) 2017-01-06 2023-05-10 Scholar Rock Inc Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
TW201833140A (zh) 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 抗fgfr抗體及使用方法
KR102537651B1 (ko) 2017-01-17 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
BR112019016204A2 (pt) 2017-02-07 2020-07-07 Daiichi Sankyo Company, Limited anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d
CA3052578A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
BR112019016344A2 (pt) 2017-02-08 2020-04-07 Novartis Ag anticorpos miméticos fgf21 e usos dos mesmos
BR112019016374A2 (pt) 2017-02-17 2020-04-07 Bristol-Myers Squibb Company anticorpos para alfa-sinucleína e usos dos mesmos
CN116785450A (zh) 2017-02-28 2023-09-22 伊缪诺金公司 具有自分解肽接头的类美登素衍生物和其缀合物
WO2018158398A1 (en) 2017-03-02 2018-09-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
MX2019010202A (es) 2017-03-03 2019-10-02 Seattle Genetics Inc Compuestos que interactuan con glicano y metodos de uso.
KR20190124304A (ko) 2017-03-13 2019-11-04 포세이다 테라퓨틱스, 인크. 조혈 줄기세포의 선택적 제거 및 대체를 위한 조성물 및 방법
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
AU2018240938A1 (en) 2017-03-24 2019-10-10 Zenyaku Kogyo Co., Ltd. Anti-IgM/B cell surface antigen bispecific antibody
KR102628323B1 (ko) 2017-03-24 2024-01-22 노바르티스 아게 심장질환 예방 및 치료 방법
CN117024534A (zh) 2017-03-30 2023-11-10 约翰霍普金斯大学 用于纯化生物大分子的超分子高亲和力蛋白结合***
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
KR102629972B1 (ko) 2017-04-13 2024-01-29 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
EP3610268A1 (de) 2017-04-15 2020-02-19 Abbott Laboratories Verfahren zur unterstützung bei der hyperakuten diagnose und bestimmung von traumatischen hirnverletzungen in einem menschlichen patienten mit frühbiomarkern
TW201839001A (zh) 2017-04-20 2018-11-01 美商伊繆諾金公司 細胞毒性苯并二氮平衍生物及其綴合物
KR20190141659A (ko) 2017-04-21 2019-12-24 스태튼 바이오테크놀로지 비.브이. 항-apoc3 항체 및 이의 사용 방법
BR112019022108A2 (pt) 2017-04-22 2020-05-12 Immunomic Therapeutics, Inc. Construções de lamp aprimoradas
BR112019022476A2 (pt) 2017-04-28 2020-05-12 Abbott Laboratories Métodos para o auxílio no diagnóstico e determinação hiperagudos de lesão cerebral traumática usando biomarcadores iniciais em pelo menos duas amostras a partir do mesmo ser humano
ES2952961T3 (es) 2017-05-01 2023-11-07 Agenus Inc Anticuerpos anti-TIGIT y métodos de uso de los mismos
BR112019023014A2 (pt) 2017-05-02 2020-05-19 Immunomic Therapeutics Inc constructos de lamp aperfeiçoados compreendendo antígenos de câncer
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
TW202330036A (zh) 2017-05-15 2023-08-01 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
AU2018272054A1 (en) 2017-05-25 2019-09-26 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018222784A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i
US20200148768A1 (en) 2017-05-31 2020-05-14 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
KR20200024158A (ko) 2017-05-31 2020-03-06 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
KR20200014379A (ko) 2017-06-05 2020-02-10 얀센 바이오테크 인코포레이티드 비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
EP3634999A1 (de) 2017-06-07 2020-04-15 Philogen S.p.A. Gefässendothelwachstumsfaktor-/antifibronectin-antikörper-fusionsproteine
GB201709379D0 (en) 2017-06-13 2017-07-26 Univ Leuven Kath Humanised ADAMTS13 binding antibodies
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
KR20200020707A (ko) 2017-06-28 2020-02-26 노파르티스 아게 요실금을 예방하고 치료하는 방법
JP7181535B2 (ja) 2017-06-30 2022-12-01 国立大学法人北海道大学 成長障害を生じない小児骨粗鬆症治療薬
JP7454945B2 (ja) 2017-07-03 2024-03-25 アボット・ラボラトリーズ 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
CA3069438A1 (en) 2017-07-11 2019-01-17 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
WO2019012015A1 (en) 2017-07-12 2019-01-17 Iontas Limited POTASIC CHANNEL INHIBITORS
KR20200027522A (ko) 2017-07-13 2020-03-12 에프. 호프만-라 로슈 아게 Pivka에 대한 신규 결합제 및 어세이
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
WO2020159504A1 (en) 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
SG11202000759XA (en) 2017-07-27 2020-02-27 Daiichi Sankyo Co Ltd Anti-cd147 antibody
US20210032364A1 (en) 2017-07-27 2021-02-04 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
US20200231682A1 (en) 2017-07-28 2020-07-23 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
EP3444275A1 (de) 2017-08-16 2019-02-20 Exiris S.r.l. Monoklonaler antikörper anti-fgfr4
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
US11745165B2 (en) 2017-08-18 2023-09-05 The Johns Hopkins University Supramolecular filamentous assemblies for protein purification
SG11202001420VA (en) 2017-08-18 2020-03-30 Cambridge Entpr Ltd Modular binding proteins
CN111511762A (zh) 2017-08-21 2020-08-07 天演药业公司 抗cd137分子及其用途
AU2018321902A1 (en) 2017-08-25 2020-02-13 Five Prime Therapeutics Inc. B7-H4 antibodies and methods of use thereof
CN109422805A (zh) 2017-08-28 2019-03-05 上海易乐生物技术有限公司 多肽及结合多肽的抗体
CN111727256A (zh) 2017-09-08 2020-09-29 波赛达治疗公司 用于嵌合配体受体（clr）-介导的条件性基因表达的组合物和方法
RU2020110056A (ru) * 2017-09-14 2021-10-14 Эбботт Диагностикс Скарборо, Инк. Обнаружение рекомбиназной полимеразной амплификации с применением зонда с двойным гаптеном
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019065964A1 (ja) 2017-09-29 2019-04-04 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
US20200262917A1 (en) 2017-10-05 2020-08-20 Daiichi Sankyo Company, Limited Composition for cytotoxic t cell depletion
US20200317783A1 (en) 2017-10-06 2020-10-08 Ono Pharmaceutical Co., Ltd. Bispecific antibody
JP7256796B2 (ja) 2017-10-13 2023-04-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
EP3700933A1 (de) 2017-10-25 2020-09-02 Novartis AG Gegen cd32b gerichtete antikörper und verfahren zur verwendung davon
TW201922294A (zh) 2017-10-31 2019-06-16 美商伊繆諾金公司 抗體-藥物結合物與阿糖胞苷之組合治療
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
US11591385B2 (en) 2017-11-09 2023-02-28 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
WO2019100052A2 (en) 2017-11-20 2019-05-23 Compass Therapeutics Llc Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
CN111727075B (zh) 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体
WO2019107384A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
JP7465210B2 (ja) 2017-11-29 2024-04-10 シーエスエル リミティド 虚血－再灌流障害の治療又は予防方法
CN111712262A (zh) 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
EP3721233A2 (de) 2017-12-09 2020-10-14 Abbott Laboratories Verfahren zur unterstützung bei der diagnose und bewertung eines patienten, der eine orthopädische verletzung erlitten hat und der eine verletzung des kopfes wie eine leichte traumatische hirnverletzung (tbi) hat oder möglicherweise erlitten hat, unter verwendung eines glialen fibrillären sauren proteins (gfap) und/oder einer ubiquitin-carboxy-terminalen hydrolase l1 (uch-l1)
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
EP3502139A1 (de) 2017-12-19 2019-06-26 Philogen S.p.A. Antikörper gegen tumorantigene
MX2020006372A (es) 2017-12-19 2020-09-03 Univ Rockefeller Variantes de dominio de fc de igg humana con funcion efectora mejorada.
WO2019131988A1 (en) 2017-12-28 2019-07-04 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
WO2019133652A1 (en) 2017-12-28 2019-07-04 Immunogen, Inc. Benzodiazepine derivatives
EP3735422A1 (de) 2018-01-05 2020-11-11 AC Immune SA Fehlgefaltete tdp-43-bindende moleküle
EP3508499A1 (de) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antikörper zum targeting von, und andere modulatoren von, einem immunglobulingen im zusammenhang mit resistenz gegen antitumor-immunantworten und verwendungen davon
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US20210363238A1 (en) 2018-01-31 2021-11-25 Motokazu Kato Therapeutic agent for asthma containing il-6 inhibitor
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
US11591399B2 (en) 2018-02-14 2023-02-28 Abba Therapeutics Ag Anti-human PD-L2 antibodies
KR20200135331A (ko) 2018-02-14 2020-12-02 비엘라 바이오, 인크. 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
BR112020017925A2 (pt) 2018-03-02 2020-12-22 Five Prime Therapeutics, Inc. Anticorpos contra b7-h4 e métodos de uso dos mesmos
KR20200129125A (ko) 2018-03-05 2020-11-17 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
WO2019172165A1 (ja) 2018-03-05 2019-09-12 学校法人埼玉医科大学 異所性骨化の治療又は予防のための医薬組成物
EP3765499A1 (de) 2018-03-12 2021-01-20 Zoetis Services LLC Anti-ngf-antikörper und verfahren dafür
NZ767596A (en) 2018-03-14 2022-01-28 Surface Oncology Inc Antibodies that bind cd39 and uses thereof
JP7333332B2 (ja) 2018-03-14 2023-08-24 エフ． ホフマン－ラ ロシュ アーゲー 抗体のアフィニティ成熟のための方法
JP2021515567A (ja) 2018-03-14 2021-06-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規抗トロポニンｔ抗体
CN112512571A (zh) 2018-03-22 2021-03-16 表面肿瘤学公司 抗il-27抗体及其用途
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
JP2021519752A (ja) 2018-03-29 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 単量体モノクローナル抗体を精製する方法
CR20200450A (es) 2018-04-02 2021-02-11 Bristol Myers Squibb Co Anticuerpos anti-trem-l y usos de los mismos
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
JP2021521273A (ja) 2018-04-12 2021-08-26 メディアファーマ エス．アール．エル． Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用
US20210070871A1 (en) 2018-04-25 2021-03-11 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies
EP3784274A1 (de) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Gegen ein tau-abgeleitetes neurotoxisches peptid gerichteter antikörper und verwendungen davon
AU2019264364A1 (en) 2018-04-30 2020-11-12 Medimmune Limited Conjugates for targeting and clearing aggregates
KR20200122409A (ko) 2018-05-10 2020-10-27 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
EP3790587A4 (de) 2018-05-11 2022-01-26 Janssen Biotech, Inc. Verfahren zur behandlung von depression mithilfe von il-23-antikörpern
WO2019222130A1 (en) 2018-05-15 2019-11-21 Immunogen, Inc. Combination treatment with antibody-drug conjugates and flt3 inhibitors
EP3793595A1 (de) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Verbesserte lamp-konstrukte mit allergenen
SG11202010977QA (en) 2018-05-16 2020-12-30 Janssen Biotech Inc Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
US20200109195A1 (en) 2018-05-21 2020-04-09 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
JPWO2019225568A1 (ja) 2018-05-21 2021-07-01 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
CR20200563A (es) 2018-05-24 2021-05-11 Janssen Biotech Inc Agentes aglutinantes de psma y usos de estos
JP2021524249A (ja) 2018-05-24 2021-09-13 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３抗体及びその使用
MA52772A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
SG11202012312UA (en) 2018-06-18 2021-01-28 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
WO2019246494A1 (en) 2018-06-21 2019-12-26 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
US20210277118A1 (en) 2018-06-21 2021-09-09 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
WO2020003172A1 (en) 2018-06-26 2020-01-02 Mor Research Applications Transthyretin antibodies and uses thereof
EP3841124A4 (de) 2018-06-29 2022-03-23 ApitBio, Inc. Anti-l1cam-antikörper und verwendungen davon
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
JP2021531007A (ja) 2018-07-20 2021-11-18 ピエール、ファーブル、メディカマン Ｖｉｓｔａに対する受容体
EP3833443A1 (de) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antigenbindende mittel, die cd277 binden, und verwendungen davon
WO2020033926A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
WO2020041360A1 (en) 2018-08-21 2020-02-27 Quidel Corporation Dbpa antibodies and uses thereof
US20220047701A1 (en) 2018-09-10 2022-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
KR20210064315A (ko) 2018-09-24 2021-06-02 얀센 바이오테크 인코포레이티드 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법
AU2019349958A1 (en) 2018-09-28 2021-05-06 Kyowa Kirin Co., Ltd. IL-36 antibodies and uses thereof
MA53811A (fr) 2018-10-03 2022-03-16 Staten Biotechnology B V Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
MA53920A (fr) 2018-10-17 2021-09-15 Janssen Biotech Inc Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
SG11202104010PA (en) 2018-10-23 2021-05-28 Scholar Rock Inc Rgmc-selective inhibitors and use thereof
GB201817309D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
GB201817311D0 (en) 2018-10-24 2018-12-05 Ucb Biopharma Sprl Antibodies
CA3117520A1 (en) 2018-10-25 2020-04-30 Polpharma Biologics Utrecht B.V. Anti-human cd89 antibodies and uses thereof
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
US20210403546A1 (en) 2018-11-05 2021-12-30 Ludwig Institute For Cancer Research Ltd. Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
CN113613726A (zh) 2018-11-05 2021-11-05 路德维格癌症研究所有限公司 人源化和变体TGF-β3特异性抗体及其方法和用途
CA3119161A1 (en) 2018-11-13 2020-05-22 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
AU2019379418A1 (en) 2018-11-14 2021-06-03 Daiichi Sankyo Company, Limited Anti-CDH6 antibody-pyrrolobenzodiazepine derivative conjugate
CA3119838A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
WO2020105621A1 (ja) 2018-11-20 2020-05-28 株式会社ペルセウスプロテオミクス 細胞内への鉄の取り込み阻害剤
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
EP3897722A4 (de) 2018-12-18 2022-09-14 Janssen Biotech, Inc. Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
WO2020128927A1 (en) 2018-12-20 2020-06-25 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
EP3898993A1 (de) 2018-12-20 2021-10-27 Poseida Therapeutics, Inc. Nanotransposon-zusammensetzungen und verfahren zur verwendung
US11447551B2 (en) 2018-12-28 2022-09-20 Sparx Bioscience Limited Binding molecules specific for claudin 18.2, compositions and methods thereof, for the treatment of cancer and other diseases
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 ***新抗原及其用途
CA3126654A1 (en) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
WO2020150496A1 (en) 2019-01-16 2020-07-23 Compass Therapeutics Llc Formulations of antibodies that bind human cd137 and uses thereof
GB201900732D0 (en) 2019-01-18 2019-03-06 Ucb Biopharma Sprl Antibodies
JP7285936B2 (ja) 2019-01-22 2023-06-02 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－７ｒアルファサブユニットに対する抗体及びその使用
CA3127748A1 (en) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
JPWO2020153467A1 (ja) 2019-01-24 2021-12-02 中外製薬株式会社 新規がん抗原及びそれらの抗原に対する抗体
JP2022524281A (ja) 2019-01-30 2022-05-02 スカラー ロック インコーポレイテッド ＴＧＦβのＬＴＢＰ複合体特異的阻害剤およびその使用
GB201902392D0 (en) 2019-02-21 2019-04-10 Cambridge Entpr Ltd Modular binding proteins
WO2020169840A1 (en) 2019-02-21 2020-08-27 Cambridge Enterprise Limited Bispecific proteins with a chimeric scaffold
DK3930847T3 (da) 2019-02-26 2024-05-06 Inspirna Inc Anti-mertk-antistoffer med høj affinitet og anvendelser deraf
US20220098290A1 (en) 2019-02-28 2022-03-31 Juntendo Educational Foundation Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
CN113825765A (zh) 2019-03-14 2021-12-21 詹森生物科技公司 用于制备抗il12/il23抗体组合物的制造方法
JP2022525179A (ja) 2019-03-14 2022-05-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための産生方法
EA202192508A1 (ru) 2019-03-14 2022-03-29 Янссен Байотек, Инк. Способы получения композиций антитела к фно
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
MA55383A (fr) 2019-03-18 2022-01-26 Janssen Biotech Inc Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
WO2020189748A1 (ja) 2019-03-19 2020-09-24 中外製薬株式会社 Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
JP2022526334A (ja) 2019-03-25 2022-05-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新たなタウ種を標的化することによるタウオパチー障害の処置の方法
AU2020246448A1 (en) 2019-03-25 2021-10-14 Daiichi Sankyo Company, Limited Anti-HER2 antibody-pyrrolobenzodiazepine derivative conjugate
JPWO2020196474A1 (de) 2019-03-25 2020-10-01
WO2020196712A1 (ja) 2019-03-27 2020-10-01 第一三共株式会社 抗体－ピロロベンゾジアゼピン誘導体コンジュゲートとｐａｒｐ阻害剤の組み合わせ
CN113811547A (zh) 2019-03-27 2021-12-17 国家医疗保健研究所 具有cd40激活特性的重组蛋白
WO2020198731A2 (en) 2019-03-28 2020-10-01 Danisco Us Inc Engineered antibodies
EP3948262A1 (de) 2019-03-29 2022-02-09 Bristol-Myers Squibb Company Verfahren zur messung der hydrophobie von chromatografischen harzen
TW202102544A (zh) 2019-04-04 2021-01-16 日商小野藥品工業股份有限公司 雙特異性抗體
CA3136398A1 (en) 2019-04-10 2020-10-15 Chugai Seiyaku Kabushiki Kaisha Method for purifying fc region-modified antibody
AU2020258384A1 (en) 2019-04-15 2021-11-04 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
US20220204608A1 (en) 2019-04-17 2022-06-30 Hiroshima University Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
CA3136888A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
EP3958908A1 (de) 2019-04-24 2022-03-02 Heidelberg Pharma Research GmbH Amatoxin-antikörper-wirkstoff-konjugate und verwendungen davon
EP3963099A1 (de) 2019-04-30 2022-03-09 Larimar Therapeutics, Inc. Frataxin-sensitive marker zur bestimmung der wirksamkeit einer frataxin ersatztherapie
CN114008073A (zh) 2019-05-23 2022-02-01 Ac免疫有限公司 抗tdp-43结合分子及其用途
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
CN113939318A (zh) 2019-05-29 2022-01-14 第一三共株式会社 抗体-药物缀合物的制剂
CN114173873A (zh) 2019-06-03 2022-03-11 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
MA56015A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
JPWO2020246563A1 (de) 2019-06-05 2020-12-10
MX2021015160A (es) 2019-06-12 2022-03-17 Novartis Ag Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
WO2021005009A1 (en) 2019-07-05 2021-01-14 Iomx Therapeutics Ag Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
BR112021005478A2 (pt) 2019-07-24 2021-06-15 H. Lundbeck A/S anticorpos anti-mglur5 e uso dos mesmos
EP4008350A4 (de) 2019-07-26 2023-06-14 Saitama Medical University Antikörper, der die extrazelluläre region von alk2/acvr1 erkennt
BR112022001473A2 (pt) 2019-07-30 2022-03-22 Ono Pharmaceutical Co Anticorpo biespecífico
EP4011918A4 (de) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. Dual-spezifisches protein
WO2021030488A1 (en) 2019-08-12 2021-02-18 Bienvenue David Leonard 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
AU2020342910A1 (en) 2019-09-04 2022-04-07 Pierre Fabre Medicament Anti-VSIG4 antibody or antigen binding fragment and uses thereof
CN114364699B (zh) 2019-09-04 2024-03-29 株式会社英仙蛋白质科学 红细胞增多症治疗药
WO2021046261A1 (en) 2019-09-05 2021-03-11 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
TW202124444A (zh) 2019-09-16 2021-07-01 美商表面腫瘤學公司 抗ｃｄ３９抗體組合物及方法
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
US20210115127A1 (en) 2019-09-25 2021-04-22 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
CN114729045A (zh) 2019-09-26 2022-07-08 斯特库比公司 对糖基化的ctla-4特异性的抗体及其使用方法
WO2021058729A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
US20220324962A1 (en) 2019-09-27 2022-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-müllerian inhibiting substance antibodies and uses thereof
CA3154710A1 (en) 2019-10-04 2021-04-08 TAE Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
JP2022552282A (ja) 2019-10-09 2022-12-15 エスティーキューブ アンド カンパニー グリコシル化ｌａｇ３に対して特異的な抗体およびその使用方法
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
EP4045061A4 (de) 2019-10-14 2024-04-17 Aro Biotherapeutics Company Cd71-bindende fibronectin-typ iii-domänen
WO2021077051A1 (en) 2019-10-18 2021-04-22 Immunomic Therapeutics, Inc Improved lamp constructs comprising cancer antigens
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
JP2022553324A (ja) 2019-10-24 2022-12-22 プロメテウス バイオサイエンシーズ，インク． Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体およびその使用
WO2021079958A1 (ja) 2019-10-25 2021-04-29 第一三共株式会社 抗ｇａｒｐ抗体と免疫調節剤の組み合わせ
WO2021087406A1 (en) 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
EP4054591A1 (de) 2019-11-04 2022-09-14 Astrazeneca AB Kombinationstherapie zur behandlung von krebs
EP3822288A1 (de) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Gegen das cd276-antigen gerichtete antikörper, und andere modulatoren gegen das cd276-antigen, und deren verwendung
US20210222133A1 (en) 2019-11-18 2021-07-22 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
US20230034677A1 (en) 2019-11-21 2023-02-02 INSERM (Institut National de la Santé et la Recherche (Médicale) Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines
EP4066858A4 (de) 2019-11-27 2023-12-27 Perseus Proteomics Inc. Therapeutisches mittel für karzinomatöse peritonitis
GB201917480D0 (en) 2019-11-29 2020-01-15 Univ Oxford Innovation Ltd Antibodies
WO2021116119A1 (en) 2019-12-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to her4 and uses thereof
JP2023507083A (ja) 2019-12-19 2023-02-21 クイデル コーポレーション モノクローナル抗体融合物
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
KR20220117915A (ko) 2019-12-20 2022-08-24 포세이다 테라퓨틱스, 인크. 항-muc1 조성물 및 사용 방법
AU2020414265A1 (en) 2019-12-24 2022-07-21 Jjp Biologics Sp. Z O.O. Anti-human HVEM (TNFRSF14) antibodies and uses thereof
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021142002A1 (en) 2020-01-06 2021-07-15 Vaccinex, Inc. Anti-ccr8 antibodies and uses thereof
WO2021142086A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CA3165713A1 (en) 2020-01-30 2021-08-05 Andrew Scharenberg Bispecific transduction enhancer
IL295387A (en) 2020-02-05 2022-10-01 Larimar Therapeutics Inc Peptide-binding proteins and their uses
EP4103609A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9 und cd7
US20230151108A1 (en) 2020-02-13 2023-05-18 UCB Biopharma SRL Bispecific antibodies against cd9 and cd137
EP4103612A1 (de) 2020-02-13 2022-12-21 UCB Biopharma SRL Bispezifische antikörper gegen cd9
US20230125234A1 (en) 2020-02-13 2023-04-27 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
WO2021160266A1 (en) 2020-02-13 2021-08-19 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
CN113248611A (zh) 2020-02-13 2021-08-13 湖南华康恒健生物技术有限公司 抗bcma抗体、其药物组合物及应用
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
MX2022010021A (es) 2020-02-18 2022-11-09 Alector Llc Anticuerpos de pilra y sus metodos de uso.
JP2023516080A (ja) 2020-03-06 2023-04-17 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
KR20220151195A (ko) 2020-03-06 2022-11-14 오엔에이 테라퓨틱스 에스.엘. 항-cd36 항체 및 암을 치료하기 위한 이의 용도
IL296241A (en) 2020-03-10 2022-11-01 Massachusetts Inst Technology Compositions and methods for immunotherapy for npm1c-positive cancer
WO2021183795A1 (en) 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
WO2021193928A1 (ja) 2020-03-27 2021-09-30 株式会社ＰｈｏｔｏＱ３ 腫瘍細胞を死滅させるための医薬
KR20220160598A (ko) 2020-03-30 2022-12-06 고쿠리츠다이가쿠호진 미에다이가쿠 이중 특이적 항체
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
JPWO2021206078A1 (de) 2020-04-06 2021-10-14
EP4132573A1 (de) 2020-04-10 2023-02-15 Vanudis GmbH Natürliche antikörper zur prophylaxe und therapie
CA3175523A1 (en) 2020-04-13 2021-10-21 Antti Virtanen Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
KR20230011295A (ko) 2020-04-14 2023-01-20 포세이다 테라퓨틱스, 인크. 암 치료에 사용하기 위한 조성물 및 방법
US20230242646A1 (en) 2020-04-21 2023-08-03 Jjp Biologics Sp. Z O.O. Humanized Anti-Human CD89 Antibodies and Uses Thereof
AU2021263754A1 (en) 2020-04-27 2022-12-01 Ensoma, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
JP2023523794A (ja) 2020-05-01 2023-06-07 ノバルティス アーゲー 人工操作免疫グロブリン
JP2023523760A (ja) 2020-05-01 2023-06-07 ノバルティス アーゲー 免疫グロブリン変異体
EP4149558A1 (de) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
US20230183366A1 (en) 2020-05-13 2023-06-15 Inserm (Institut National De La Santé Et De La Recherch Médicale) Recombinant proteins with ox40 activating properties
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
JP2023528235A (ja) 2020-05-17 2023-07-04 アストラゼネカ・ユーケイ・リミテッド ＳＡＲＳ－ＣｏＶ－２抗体、並びにこれを選択及び使用する方法
WO2021261546A1 (ja) 2020-06-24 2021-12-30 国立大学法人 東京大学 光増感色素
EP4175668A1 (de) 2020-07-06 2023-05-10 iOmx Therapeutics AG Igv von igsf11 (vsig3) bindende antikörper und verwendungen davon
BR112023000482A2 (pt) 2020-07-16 2023-01-31 Novartis Ag Anticorpos antibetacelulina, fragmentos dos mesmos e moléculas de ligação multiespecíficas
CN116507636A (zh) 2020-07-20 2023-07-28 阿斯利康(英国)有限公司 SARS-CoV-2蛋白、抗SARS-CoV-2抗体以及它们的使用方法
MX2023000854A (es) 2020-07-28 2023-02-15 Chugai Pharmaceutical Co Ltd Formulacion de jeringa precargada con aguja con protector de aguja que contiene nuevo anticuerpo modificado.
MX2023001120A (es) 2020-07-31 2023-02-22 Chugai Pharmaceutical Co Ltd Composicion farmaceutica que comprende una celula que expresa un receptor quimerico.
JP2023537331A (ja) 2020-07-31 2023-08-31 バイオ－テラ ソリュ－ションズ，エルティーディー． Ｃｄ４７抗体及びその応用
EP4193149A1 (de) 2020-08-04 2023-06-14 Abbott Laboratories Verbesserte verfahren und kits zum nachweis von sars-cov-2-protein in einer probe
US11484604B2 (en) 2020-08-07 2022-11-01 Fortis Therapeutics, Inc. Immunoconjugates targeting CD46 and methods of use thereof
WO2022034228A1 (en) 2020-08-14 2022-02-17 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
CN116761821A (zh) 2020-08-18 2023-09-15 赛福伦有限责任公司 抗par-2抗体及其使用方法
CN114106173A (zh) 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
US20240092890A1 (en) 2020-08-27 2024-03-21 Juntendo Educational Foundation Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition
EP4204448A2 (de) 2020-08-27 2023-07-05 cureab GmbH Anti-golph2-antikörper zur makrophagen- und dendritischen zelldifferenzierung
WO2022047359A1 (en) 2020-08-31 2022-03-03 Berg Llc Protein biomarkers for pancreatic cancer
CA3192526A1 (en) 2020-09-04 2022-03-10 Rutgers, The State University Of New Jersey Sars-cov-2 vaccines and antibodies
AR123480A1 (es) 2020-09-11 2022-12-07 Medimmune Ltd Moléculas de unión terapéuticas
WO2022053685A2 (en) 2020-09-12 2022-03-17 Medimmune Limited A scoring method for an anti-b7h4 antibody-drug conjugate therapy
JPWO2022075439A1 (de) 2020-10-08 2022-04-14
EP4229081A1 (de) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Für sars-cov-2-rezeptor-bindungsdomäne spezifischer antikörper und therapeutische verfahren
MX2023004436A (es) 2020-10-15 2023-05-08 UCB Biopharma SRL Moleculas de union que multimerizan cd45.
WO2022084400A1 (en) 2020-10-20 2022-04-28 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
EP3992205A1 (de) 2020-11-03 2022-05-04 Rheinische Friedrich-Wilhelms-Universität Bonn Verbindung zum binden des sars coronavirus-2 spike-proteins
US20230406961A1 (en) 2020-11-03 2023-12-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
CN116472288A (zh) 2020-11-06 2023-07-21 诺华股份有限公司 抗体Fc变体
US20230406921A1 (en) 2020-11-12 2023-12-21 Mabwell (shanghai) Bioscience Co., Ltd. Antibody and preparation method therefor
WO2022106205A1 (en) 2020-11-18 2022-05-27 Rheinische Friedrich-Wilhelms-Universität Bonn Corona virus spike protein binding compounds
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
US20220170948A1 (en) 2020-12-01 2022-06-02 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
US20240052042A1 (en) 2020-12-14 2024-02-15 Novartis Ag Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
EP4271998A1 (de) 2020-12-30 2023-11-08 Abbott Laboratories Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
CN117425500A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗dll3抗体-药物缀合物
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR20230147099A (ko) 2021-01-28 2023-10-20 백신벤트 게엠베하 B 세포 매개 면역 반응을 조절하기 위한 방법 및 수단(method and means for modulating b-cell mediated immune responses)
KR20230137393A (ko) 2021-01-28 2023-10-04 얀센 바이오테크 인코포레이티드 Psma 결합 단백질 및 이의 용도
WO2022162203A1 (en) 2021-01-28 2022-08-04 Vaccinvent Gmbh Method and means for modulating b-cell mediated immune responses
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
US20220378929A1 (en) 2021-02-25 2022-12-01 MediBoston Limted Anti-her2 antibody-drug conjugates and uses thereof
WO2022184853A1 (en) 2021-03-03 2022-09-09 Pierre Fabre Medicament Anti-vsig4 antibody or antigen binding fragment and uses thereof
WO2022187591A1 (en) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CN117751138A (zh) 2021-03-12 2024-03-22 詹森生物科技公司 用抗il23特异性抗体治疗银屑病关节炎的安全且有效的方法
TW202302143A (zh) 2021-03-12 2023-01-16 日商中外製藥股份有限公司 重症肌無力症之治療或預防用之醫藥組合物
AU2022232007A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
EP4308694A1 (de) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosierschemata zur mobilisierung hämatopoetischer stammzellen für stammzelltransplantationen bei patienten mit multiplem myelom
WO2022195028A2 (en) 2021-03-18 2022-09-22 Medimmune Limited Therapeutic binding molecules
EP4317435A1 (de) 2021-03-29 2024-02-07 Daiichi Sankyo Company, Limited Stabiles multispezifisches molekül und verwendung davon
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
WO2022216798A1 (en) 2021-04-06 2022-10-13 Berg Llc Protein markers for the prognosis of breast cancer progression
EP4320440A1 (de) 2021-04-06 2024-02-14 BPGbio, Inc. Proteinmarker für östrogenrezeptor (er)-positiven luminalen a(la)-ähnlichen und luminalen b1 (lb1)-ähnlichen brustkrebs
US20230059578A1 (en) 2021-04-06 2023-02-23 Berg Llc Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
AU2022255506A1 (en) 2021-04-08 2023-11-09 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
CN113156121B (zh) * 2021-04-16 2021-12-07 苏州东尼生物技术有限公司 一种用于检测人甲状腺球蛋白的胶体金试纸条
EP4334353A1 (de) 2021-05-04 2024-03-13 Regeneron Pharmaceuticals, Inc. Multispezifische fgf21-rezeptoragonisten und deren verwendungen
EP4334348A1 (de) 2021-05-07 2024-03-13 Surface Oncology, LLC Anti-il-27-antikörper und verwendungen davon
AU2022279156A1 (en) 2021-05-18 2023-11-02 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
CA3220629A1 (en) 2021-05-28 2022-12-01 Tobin J. CAMMETT Methods for detecting cm-tma biomarkers
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
CA3222291A1 (en) 2021-06-14 2022-12-22 Jaime MARINO Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
IL308959A (en) 2021-06-18 2024-01-01 Nammi Therapeutics Inc Fusion protein composition(s) containing masked type I interferons (IFNalpha and IFNbeta) for use in cancer therapy and methods thereof
AU2022299185A1 (en) 2021-06-23 2024-01-25 Scholar Rock, Inc. A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
CA3221281A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
KR20240032991A (ko) 2021-07-09 2024-03-12 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 생성을 위한 제조 방법
US20230040065A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-TNF Antibody Compositions
IL309987A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-IL12/IL23 antibody compositions
WO2023285878A1 (en) 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
WO2023286854A1 (ja) 2021-07-16 2023-01-19 ブライトパス・バイオ株式会社 抗Ｔｉｍ－３抗原抗体または抗体誘導体およびその用途
AU2022320051A1 (en) 2021-07-30 2024-01-25 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
WO2023027164A1 (ja) 2021-08-26 2023-03-02 株式会社ペルセウスプロテオミクス Ｒｏｓ（活性酸素種）産生増強剤
AU2022339759A1 (en) 2021-08-31 2024-03-07 Abbott Laboratories Methods and systems of diagnosing brain injury
TW202323289A (zh) 2021-08-31 2023-06-16 日商大正製藥股份有限公司 抗生長激素抗體
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
TW202325733A (zh) 2021-09-03 2023-07-01 美商Ｇｏ治療公司 抗醣化-lamp1抗體及其用途
CA3231632A1 (en) 2021-09-15 2023-03-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
CN117999098A (zh) 2021-09-24 2024-05-07 光爱科技公司 用于杀死肿瘤细胞的医药品
CA3232176A1 (en) 2021-09-30 2023-04-06 Beth MCQUISTON Methods and systems of diagnosing brain injury
AU2022360244A1 (en) 2021-10-04 2024-04-11 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
WO2023057871A1 (en) 2021-10-04 2023-04-13 Novartis Ag Surfactant stabilizers
JPWO2023058723A1 (de) 2021-10-08 2023-04-13
WO2023073615A1 (en) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023079494A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Corticosteriod reduction in treatment with anti-cd38 antibodies
EP4177266A1 (de) 2021-11-05 2023-05-10 Katholieke Universiteit Leuven Neutralisierende humane anti-sars-cov-2-antikörper
WO2023084488A1 (en) 2021-11-15 2023-05-19 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023090361A1 (ja) 2021-11-16 2023-05-25 国立大学法人鳥取大学 改変ｄ領域を含むヒト免疫グロブリン重鎖遺伝子座を有する哺乳動物人工染色体ベクター、及びそのベクターを保持する細胞又は非ヒト動物
WO2023088959A1 (en) 2021-11-16 2023-05-25 Ac Immune Sa Novel molecules for therapy and diagnosis
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023129942A1 (en) 2021-12-28 2023-07-06 Abbott Laboratories Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
WO2023141576A1 (en) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
US20230295348A1 (en) 2022-01-24 2023-09-21 Novimmune Sa Composition and methods for the selective activation of cytokine signaling pathways
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
TW202342519A (zh) 2022-02-16 2023-11-01 瑞士商Ａｃ 免疫有限公司 人源化抗ｔｄｐ－４３結合分子及其用途
WO2023166081A1 (en) 2022-03-02 2023-09-07 Heidelberg Immunotherapeutics Gmbh Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
US20240002544A1 (en) 2022-03-07 2024-01-04 Novimmune Sa Cd28 bispecific antibodies for targeted t cell activation
WO2023169896A1 (en) 2022-03-09 2023-09-14 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
WO2023170216A1 (en) 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
WO2023175171A1 (en) 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Bk polyomavirus antibodies and uses thereof
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
US20230357851A1 (en) 2022-04-06 2023-11-09 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring frataxin-replacement therapy
US20230355792A1 (en) 2022-04-07 2023-11-09 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
WO2023194565A1 (en) 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
WO2023203177A1 (en) 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
TW202400658A (zh) 2022-04-26 2024-01-01 瑞士商諾華公司 靶向ｉｌ—１３和ｉｌ—１８的多特異性抗體
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240201A1 (en) 2022-06-08 2023-12-14 Larimar Therapeutics, Inc. Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024006961A1 (en) 2022-07-01 2024-01-04 Neoleukin Therapeutics, Inc. Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024050354A1 (en) 2022-08-31 2024-03-07 Washington University Alphavirus antigen binding antibodies and uses thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024054436A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
WO2024052503A1 (en) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024056668A1 (en) 2022-09-12 2024-03-21 Institut National de la Santé et de la Recherche Médicale New anti-itgb8 antibodies and its uses thereof
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
WO2024084052A1 (en) 2022-10-21 2024-04-25 Novimmune Sa Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
WO2024089418A1 (en) 2022-10-24 2024-05-02 Cancer Research Technology Limited Tumour sensitisation to checkpoint inhibitors with redox status modifier
WO2024089417A1 (en) 2022-10-24 2024-05-02 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3588239T3 (de) 1985-03-30 2007-03-08 Kauffman, Stuart A., Santa Fe Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
WO1988006630A1 (en) * 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) * 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
DE3744595A1 (de) 1987-12-31 1989-07-13 Andreas Dr Plueckthun Verfahren zur gentechnischen herstellung von antikoerpern
DE768377T1 (de) * 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5688666A (en) * 1988-10-28 1997-11-18 Genentech, Inc. Growth hormone variants with altered binding properties
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016842A1 (en) * 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
AU652539B2 (en) * 1989-05-16 1994-09-01 Medical Research Council Co-expression of heteromeric receptors
CA2016841C (en) * 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
EP0486526B2 (de) 1989-08-07 2001-03-07 Peptech Limited Bindeligande für tumornekrosisfaktor
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) * 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
ATE212059T1 (de) 1990-02-15 2002-02-15 Methoden zur identifizierung heterofunktionaler fusionsproteine
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US7063943B1 (en) * 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
AU665190B2 (en) * 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5258289A (en) 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
IL99552A0 (en) * 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US6893845B1 (en) * 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
IE65042B1 (en) 1990-11-08 1995-10-04 Buchlane Investments Ltd A work piece stabilising device
ATE164395T1 (de) * 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
WO1992011272A1 (en) 1990-12-20 1992-07-09 Ixsys, Inc. Optimization of binding proteins
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
WO1992018619A1 (en) * 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE69230142T2 (de) * 1991-05-15 2000-03-09 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
US6225447B1 (en) * 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) * 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE4122599C2 (de) * 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5830663A (en) 1991-08-10 1998-11-03 Medical Research Council In situ recombinant PCR within single cells
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methoden zur Herstellung humanisierter Antikörper
PT1696031E (pt) * 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0616640B1 (de) 1991-12-02 2004-09-01 Medical Research Council Herstellung von Antikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken.
DE69331278T2 (de) * 1992-09-04 2002-07-18 Scripps Research Inst Phagemiden die einen oberflächenrezeptor und ein heterologes oberflächenprotein co-exprimieren
DK0672142T3 (da) * 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
PT859841E (pt) 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
US5916605A (en) * 1996-09-27 1999-06-29 Dynisco Hotrunners, Inc. Valve actuated injection molding apparatus
US5935523A (en) * 1997-05-29 1999-08-10 Medical Laboratory Automation, Inc. Apparatus for accessing a sealed container
CA2527694C (en) * 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs

Also Published As

Publication number Publication date
US20030190674A1 (en) 2003-10-09
DE69233782D1 (de) 2010-05-20
ES2227512T3 (es) 2005-04-01
PT1696031E (pt) 2010-06-25
US6582915B1 (en) 2003-06-24
US6555313B1 (en) 2003-04-29
US6521404B1 (en) 2003-02-18
ES2341666T3 (es) 2010-06-24
ATE275198T1 (de) 2004-09-15
US20070232790A1 (en) 2007-10-04
DK1024191T3 (da) 2008-12-08
US5885793A (en) 1999-03-23
ES2313867T3 (es) 2009-03-16
ATE463573T1 (de) 2010-04-15
US20090325815A1 (en) 2009-12-31
US7195866B2 (en) 2007-03-27
US20080050359A1 (en) 2008-02-28
ATE408012T1 (de) 2008-09-15
US6593081B1 (en) 2003-07-15
US6544731B1 (en) 2003-04-08
WO1993011236A1 (en) 1993-06-10
PT1024191E (pt) 2008-12-22

Similar Documents

Publication Publication Date Title
DE69233745D1 (de) Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
CA2124460A1 (en) Production of anti-self antibodies from segment repertoires and displayed on phage
Lavinder et al. Identification and characterization of the constituent human serum antibodies elicited by vaccination
ATE473754T1 (de) Verfahren zur manipulation der zelldifferenzierung
WO2003050531A3 (en) Method for displaying loops from immunoglobulin domains in different contexts
CA2119930A1 (en) Production of chimeric antibodies - a combinatorial approach
TW200516083A (en) Methods for making dual specificity antibodies
DE69022982T2 (de) Humanisierte antikörper.
DK1054018T3 (da) Fab-fragmentbiblioteker og fremgangsmåde til anvendelse deraf
DE69619493D1 (de) Polypeptid-dendrimer komplexe
ES2165851T3 (es) Proteinas multivalentes que se unen a antigenos.
US11634487B2 (en) Diagnostic method
DE69029808T2 (de) Monoklonale antikörper
DK1328814T3 (da) Fremgangsmåde til identifikation in vivo af intracellulære epitoper
JPWO2021097365A5 (de)
EP0331514A3 (de) Prüfung der Deletion oder des Mangels an Protein von Duchenne-Muskeldystrophie
Han et al. Antibodies to the DNA-directed RNA polymerase II subunit RPB1 occur with highest frequency in centenarians
Coe Specificity of antibody produced in the bullfrog (Rana catesbeiana)
Paus et al. TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
NO974793L (no) Fremgangsmåte til fremstilling av et monoklonalt antistoff mot Onkostatin M, eller et fragment derav
PUTNAM et al. Tentative structure of human IgM immunoglobulin
Wasniowska et al. An immunoblotting procedure for screening glycophorins and band 3 protein in the same blots: Identification of glycophorin and band 3 variant forms
AR127177A1 (es) Polipéptidos de unión a antígeno, complejos de polipéptidos de unión a antígeno y métodos de uso de los mismos
Davis et al. Monoclonal antibodies in simultaneous marking ELISA systems
EA200200730A1 (ru) Способ идентификации веществ, имитирующих эпитопы млекопитающих

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MEDICAL RESEARCH COUNCIL, LONDON, GB

Owner name: MEDIMMUNE LIMITED, CAMBRIDGE, CAMBRIDGESHIRE, GB

8364 No opposition during term of opposition